,publication,pmid,id,gene,inheritance,evidence_type,phenotype_quality,phenotyping_method_notes,genomic_variants,coding_variants,protein_variants,score_justification,score_range,initial_score,final_score
0,Alshaimaa Alzahrani et al. (2023): Case Report: Clinical delineation of CACNA1D mutation: New cases and literature review,37122292.0,Single Proband,CACNA1D,": Paternally Inherited (The father who was 65 years-old at the time of death, had ID and developed major depressive disorder with catanonic features and nihilistic delusion, followed by rapid progressive dementia. He died after experiencing prolonged seizures followed by post-cardiac arrest. He showed good interpersonal communication. Furthermore, the sister, a 30 years-old woman, who also inherited the missense variant had severe ID with aggressive behaviors and sleep disorders. She was diagnosed with bipolar disorder and psychosis. The mother is healthy and she does not carry the missense variant)",Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: Diagnosis of ASD and severe ID was established at the age of 6 years in a developmental clinic, according to the DSM-5 criteria. Furthermore, the clinical profile of the patient is consistent with the main features of ASD, including repetitive patterns of behavior and deficits in social-emotional reciprocity",g.53783353C>G,,"p.R1125G,p.R1145G","Default score applied.
Paternally inherited missense variant identified through whole exome sequencing and validated by Sanger sequencing. The variant is detected in a gene in which non-synonymous variation is the known disease mechanism. The variant is located within one of the 4 transmembrane repeats that form the pore of the channel, which is a mutational hotspot. Although the variant is absent in gnomAD, a different amino-acid substitution is reported (p.S672W). On the other hand, the p.S672L missense variant is present on ClinVar, where it is classified as likely pathogenic. This variant has been detected in additional unrelated case with similar clinical phenotype characterized by neurodevelopmental phenotype, reported by Zhou X et al. (2022) Row: 8 and Hofer NT et al. (2020) Row: 34. Suggesting that the variant is pathogenic. The variant was scored under the criteria of predicted/proven null although it causes a gain of function effect, based on functional evidence that supports the pathogenicity of the variant. Hofer NT et al. (2020) PMID: 31921405 performed a series of experiments to investigate the effect of the variant. It was shown that the mutant protein induces an increase in calcium influx and hence, higher intracellular calcium levels. The missense variant changes the voltage-dependence activation and steady state-inactivation to more negative voltages, suggesting a gain-of-function effect. This is consitent with the main mechanism of the disease associated with the gene. The authors further investigated the non-synonymous variant (p.S672W), which has been detected in healthy individuals in gnomAD. Consistent with the disease mechanism of the gene, this missense variant has an opposite effect on channel activity, shifting the voltage-dependence activation and steady state inactivation to more positive voltages, indicating a loss of function effect. Furthemore, the variant co-segregated with the phenotype in the family. Based on all this evidence, the p.S672L is clearly pathogenic. Thus, he default score of 1.5 was applied, but no additional upgrades were assigned. 
High confidence in phenotypic quality.  ",0-2,1.0,1.5
10,Hofer NT et al. (2020): Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder,31921405.0,"Single case reported in the current study (This patient was originally identified by the deciphering developmental disorder, DDD study 2015, PMID: 25533962. However, a detail phenotypic description was not provided in this former study. Thus, the case was reported under the current study. This patient is reported on the DECIPHER database with the ID: 262954. The case has a monozygotic twin brother, DECIPHER ID: 262956)",CACNA1D,: de novo,Variant is de novomissense,Low Confidence in Phenotype ,ASD: Although both twin borthers were diagnosed with ASD at the age of 11 years-old. The diagnostic tools and criteria employed to determine the diagnosis were not described in the study,g.41203521C>A,c.894C>A,p.C298*,"Default score upgraded after modification for functional and phenotypic evidence. 
De novo missense variant identified through whole exome sequencing, in a gene in which non-synonymous variation is the known disease mechanism. The variant is absent in gnomAD and affects a highly conserved residue in a functional domain that is a mutational hotspot. The score was upgraded for functional evidence showing that the non-synonymous substitution has a gain-of-function effect on protein activity. The authors performed a series of experiments to investigate the effect of the variant. It was shown that the mutant protein induces an increase in calcium influx and hence, higher intracellular calcium levels. The missense variant changes the voltage-dependence activation and steady state-inactivation to more negative voltages, suggesting a gain-of-function effect. This is consitent with the main mechanism of the disease associated with the gene.  On the other hand, the additional framehsift variant identified in the KIF22 gene is unlikely to be associated with the neurodevelopmental phenotype of the proband. The authors further investigated the non-synonymous variant (p.S652W), which has been detected in healthy individuals in gnomAD. Consistent with the disease mechanism of the gene, this missense variant has an opposite effect on channel activity, shifting the voltage-dependence activation and steady state inactivation to more positive voltages, indicating a loss of function effect. Based on all this evidence, the p.S672L is pathogenic, thus the score was upgraded (+0.5). Although the same variant was detected in a case reported by Zhou X. et al. (2022) PMID: 35982159 (Row: 8), based on genotypic evidence these cases are more likely to be unrelated. The additional variants detected in these cases are different. Therefore, the current case was also scored. 
On the other hand, the score was downgraded for low confidence in phenotypic quality. The diagnostic methods used to determine the diagnosis of ASD were not provided and no further detail of ASD-relevant traits were described in the study (-0.25). ",0-1,0.0,0.75
13,"Jiao J, et al. (2019): Identification of De Novo JAK2 and MAPK7 Mutations Related to Autism Spectrum Disorder Using Whole-Exome Sequencing in a Chinese Child and Adolescent Trio-Based Sample",31838722.0,Family A18 (ID: ND171202291),CACNA1D,: de novo,Variant is de novomissense,High Confidence in Phenotype,"ASD: Patients were recruited from the department of the West China Mental Health Center of Sichuan Universtiy, special education schools and nursery schools in Chengdu city. Diagnosis of ASD was determined following a two stepp approach. First, a child psychiatrist used the DSM-V criteria to determine a preliminary clinical diagnosis in children. Then, the patients with ASD were diagnosed independently by 2 well-trained child psychiatrists using the ADOS and ADI-R. Cases with known syndromic conditions such as congenital heart disease, Rett syndrome, Down syndrome, were excluded",g.41204491C>G,c.1084C>G,p.R362G,"Default score applied. 
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The variant affects a highly conserved residue which is part of the pore forming domain of the channel. This is a mutational hotspot of most pathogenic mutations. The variant is absent in gnomAD. However, the score was not upgraded due to lack of functional evidence that supports the pathogenicity of the variant. On the other hand, the additional genes with variants are not predicted to be involved in ASD or neruodevelopmental phenotypes.
High confidence in phenotypic quality. ",0-1,0.0,0.5
14,"Long S, et al. (2019): The Clinical and Genetic Features of Co-occurring Epilepsy and Autism Spectrum Disorder in Chinese Children",31139143.0,P051,CACNA1D,: de novo,Variant is de novomissense,High Confidence in Phenotype ,"ASD: The study retrospectively recruited patients with a comorbid diagnosis of ASD and epilepsy from the National Children's Medical Center, Shanghai, China. Primary data were collected from electronic clinical history systems and medical records using key words ""Autism/ASD and epilepsy/seizure"". ASD was first assessed using the Autism Behavior Checklist, completed by parents, and probands with at least 18-months old. When the score was >61, ASD was considered. Then, all ASD candidate patients were diagnosed by qualified and experienced neurologists and psychologists using the Diagnostic and Statistical Manual of Mental Disorder V (DSM-V). Diagnosis was based on evidence available from the ADOS and the ADI-R. ASD severity was assessed using the DSM-V criteria and categorized into mild, moderate or severe. Patients with ASD-like features but failed to met the diagnostic criteria were excluded",g.41204655A>C,c.1171-2A,,"Default score applied. 
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The variant affects a highly conserved residue which is part of the pore forming domain of the channel. This is a mutational hotspot of most pathogenic mutations. The variant is absent in gnomAD. However, the score was not upgraded due to lack of functional evidence that supports the pathogenicity of the variant. No additional variants were detected in this case. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
15,"Garza-Lopez E, et al. (2018): Role of a conserved glutamine in the function of voltage-gated Ca2+ channels revealed by a mutation in human CACNA1D.",30054272.0,Single Proband,CACNA1D,: Paternally and Maternally Inherited (The parents are heterozygous for the variant. The parents are from a family with a high degree of consanguinity),Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined. However, the proband presents some symptoms that are consistent with the main features of ASD, including limited eye contact and hyperactivity. Information regarding the presence of stereotypic behavior were not provided",g.41201830delA,c.369delA,p.N124Tfs*97,"Default score downgraded for phenotypic evidence. 
Homozygous missense variant inherited from both parents identified through whole exome sequencing. Both parents are heterozygous for the variant. The variant affects a highly conserved glutamine residue which is also conserved in all genes from the calcium channel family. The glutamine residue is located in the extracellular region that connects the transmembrane helices S1-S2 of the second domain. Functional experiments performed by the authors of this study showed that the variant is pathogenic and alters the function of the channel. The variant affects the availability of the channel at the cell surface by impairing protein trafficking, resulting in reduced current densities. On the other hand, the variant also exerts a gain of function effect on the channel activity. The non-synonymous variant impairs the inactivation kinetics resulting in prolonged Calcium currents. This is consistent with the disease mechanism associated with the gene. For this reason, the variant was interpreted as pathogenic with default score 1.5. But no additional upgrades were applied. The homozygous missense variant in OTOG gene is clinically relevant, since it is associated with autosomal recessive deafness. But the gene is not associated with ASD. 
The score was downgraded for medium confidence in phenotypic quality (-0.25)",0-2,1.0,1.25
17,"De Rubeis S, et al. (2014): Synaptic, transcriptional and chromatin genes disrupted in autism",25363760.0,10C105736,CACNA1D,: Paternally Inherited,Other variant type not predicted/proven null (not de novo),High Confidence in Phenotype ,"ASD: Proband is part of the Autism Sequencing Consortium (ASC), an international collaboration that includes ASD simplex, multiplex Families and case control studies. All centers used standardized tools to evaluate the clinical phenotype of the probands including the ADOS, ADI-R and diagnosis was ascertain according to the DSM-IV or ICD-10 criteria (ST1)",g.41206206G>A,c.1710G>A,p.W570*,"Default score applied.
Paternally inherited missense variant identified through whole exome sequencing but no further validation performed. The variant affects a highly conserved residue located in a mutational hotspot in a gene where non-synonymous variation is a known disease mechanism. The variant is absent in gnomAD. No functional evidence is available regarding the effect of this variant on protein function, thus the score was not upgraded. 
High confidence in phenotypic quality. ",0-0.1,0.0,0.1
20,Miyake N et al. (2023): Molecular diagnosis of 405 individuals with autism spectrum disorder,36973392.0,Patient ID 9852,DDX3X,: de novo,Variant is de novomissense,High Confidence in Phenotype,ASD: The probands included in the study were clinically diagnosed with ASD based on the Diagnostic and Statistical Manual of Mental Disorders-V,g.41206224T>G,c.1728T>G,p.Y576*,"Default score applied. 
De novo missense variant identified through family-based whole exome sequencing and validated by Sanger sequencing. The variant affects a highly conserved residue located within the Helicase ATP-binding domain and this particular residue is involved in RNA binding. The missense substitution is absent in gnomAD, but reputable databases classified this variant as pathogenic. Furthermore, functional evidence supports the pathogenicity of the variant through in vitro and in vivo studies. The variant results in loss of function, consistent with the disease mechanism of the gene. Altough functional evidence is available for this variant, the score was not upgraded since it is a recurrent mutation detected in several cases with DDX3X syndrome. This decision was taken to prevent overestimating the actual score of the gene. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
21,Miyake N et al. (2023): Molecular diagnosis of 405 individuals with autism spectrum disorder,36973392.0,Patient ID 19016,DDX3X,: de novo,Variant is de novomissense,High Confidence in Phenotype,ASD: The probands included in the study were clinically diagnosed with ASD based on the Diagnostic and Statistical Manual of Mental Disorders-V,g.41206602C>T,c.1807C>T,p.R603*,"Default score applied.
De novo missense variant identified through family-based whole exome sequencing. The variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot for this gene. The non-synonymous variant is absent in gnomAD. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
22,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 1,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41203598C>A,c.971C>A,p.P324Q,"Default score downgraded for phenotypic evidence. 
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The variant affects an evolutionarily conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot for the gene. The missense substitution is absent in gnomAD and in silico analysis supports a damaging effect on protein function, but functional evidence is not available. 
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on assessment using gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify those cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
23,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 6,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41205562T>G,c.1666T>G,"p.Y466D,p.Y556D","Default score downgraded for phenotypic evidence.
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The variant affects a highly conserved residue located within the ATP-binding domain, which represents a mutational hotspot. In particular, this residue is involved in RNA binding. The missense substitution is absent in gnomAD. 
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify those cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
24,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 8,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41202557dupT,c.632dup,p.I211fs,"Default score downgraded for phenotypic evidence. 
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The variant is absent in gnomAD, while reputable resources classified this variant as likely pathogenic. Functional evidence supports the pathogenicity of the variant showing that it resulted in complete loss of helicase activity, consistent with the disease mechanism of the gene. However, the score was not upraded since this is a recurrent mutation detected in additional patients with DDX3X syndrome. This decision was made to avoid overestimating the actual score of the gene. 
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify those cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
25,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 15,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41206603G>A,"c.1805G>A,c.1808G>A","p.R602Q,p.R603Q","Default score downgraded for phenotypc evidence.
De novo in-frame deletion variant identified through whole exome sequencing and validated by Sanger sequencing. The indel eliminates a single, highly conserved residue which is not part of a functional domain of the protein. The variant is absent in gnomAD, while reputable resources reported the variant as pathogenic. Furthermore, it is a recurrent variant detected in additional, unrelated cases with DDX3X syndrome. 
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
26,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 16,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41205795-41205796del,c.1535_1536del,p.H512Rfs*5,"Default score downgraded for phenotypic evidence. 
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The non-synonymous variant affects a highly conserved residue which is not part of a functional domain of the protein. The missense substitution is absent in gnomAD but reputable resources classified the variant as pathogenic. It is a recurrent mutation among cases with DDX3X syndrome. 
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify those cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
27,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 17,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41206174-41206176del,"c.1630_1632delCTT,c.1678_1680del","p.L544del,p.L560del","Default score downgraded for phenotypic evidence. 
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The non-synonymous variant affects a highly conserved residue which is not part of a functional domain of the protein. The missense substitution is absent in gnomAD.
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify those cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
28,Dai Y et al. (2022): Expansion of Clinical and Genetic Spectrum of DDX3X Neurodevelopmental Disorder in 23 Chinese Patients,35392274.0,Female 18,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The Social Communication Questionnaire (SCQ)-Lifetime version was applied as a primary screening tool to assess risk for autism spectrum disorder. This tool is a brief 40-item, parent-report clinical survey, which had been widely used as a primary screener to assess risk for autism spectrum disorder. The SCQ was conducted in a semi-structured parent interview conducted by a trained clinician or researcher. A complete developmental history was needed to be the reference. Based on this criteria, scores above the cut off of 12 suggested individuals were above the ""at risk"" threshold for ASD, and suggests that further comprehensive evaluations should be undertaken",g.41206571A>A,,p.F593fs,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. The missense variant affects a highly conserved residue located within the Helicase C-terminal domain. The non-synonymous change is absent in gnomAD but it is reported in reputable resources a pathogenic. The missense substitution affects a residue that is recurrently mutated in cases with DDX3X syndrome. 
However, the score was downgraded due to low confidence in phentoypic quality (-0.25). A conventional diagnosis of ASD, based on gold-standard criteria, was not established for this case. Instead, the Social Communication Questionnaire was employed as a screening tool to identify those cases who are above the ""at risk"" threshold for ASD. Since only a screening tool for ASD was employed, the score was downgraded. ",0-1,0.0,0.25
29,Stefaniak U et al. (2022): Autistic-like Behaviors Associated with a Novel Non-Canonical Splice-Site DDX3X Variant: A Case Report of a Rare Clinical Syndrome,35326346.0,Single case Report,DDX3X,": Likely de novo (The variant was not detected in the maternal DNA sample. However, the paternal sample was not available for segregation studies)",Variant is de novo non-canonical splice site,Low Confidence in Phenotype,"ASD: The case present some but not all features associated with ASD diagnosis. On the one hand, the case presents ASD-like behaviors such as stereotypy, problems with imitation movements and dysfunction with sensory processing: tactile defensiveness, lack of speech, and occasional sleep disturbances. On the other hand, she presented features that did not fit ASD. For instance, curiosity, a desire for social interaction, spontaneous behaviors. These features made a neurologist question the diagnosis of ASD. The patient received a diagnosis of ASD as a result of a psychologist test at three years of age. Then, she started atteding a kindergarten for children with ASD and there, her behavior started to regress. Her behavior was also assessed with The Vinland Behavior Scales (VABS)",g.41201831G>T,c.368G>T,p.G123V,"Default score downgraded for genotypic and phenotypic evidence.
Likely de novo non-canonical donor splice variant identified through exome sequencing of the coding and exon/intron boundaries of 3750 genes, which have been implicated with clinical phenotypes. Given the moderate number of genes included in the panel, the score was downgraded (-0.25). The score was further downgraded since inheritance pattern was not experimentally validated. Although the variant was not detected in the mother, paternal sample was not available for segregation analysis (-0.1). The variant is absent in gnomAD. In silico analysis predicted that the variant affects mRNA splicing, but experimental evidence is not available. 
The score was further downgraded due to low confidence in the phenotypic quality (-0.5). Although the case initially received a diagnosis of ASD based on the observation of some features consitent with ASD diagnosis during a psychological test, further analysis made by a neurologist questioned the diagnosis of ASD. The case presents some features consitent with ASD, including stereotypy, problems with imitation movements and dysfunction with sensory processing: tactile defensiveness, lack of speech, and occasional sleep disturbances. On the other hand, she presented features that did not fit ASD profile. For instance, curiosity, a desire for social interaction, spontaneous behaviors. Due to the lack of a consensus diagnosis using gold-standard criteria, the phenotype quality was determined as low. ",0-1.5,1.0,0.15
30,Sun et al. (2022): Case Report: De novo DDX3X mutation caused intellectual disability in a female with skewed X-chromosome inactivation on the mutant allele,36299587.0,Single case report (Individual II-1),DDX3X,: de novo,Variant is de novomissense,High Confidence in Phenotype,"ASD: Diagnosis of ASD was determined at the age of 7 years old by behavioral assessment with the childhood autism rating scale (CARS) and the autistic behavior checklist. Both assessments tools showed concordant results, indicating that the proband is above the threshold for ASD",g.41204570A>G,,p.E388G,"Default score applied.
De novo in-frame duplication variant identified through whole exome sequencing and validated by Sanger sequencing. The in-frame variant resulted in the duplication of 6 amino-acids in a non-repetitive region, thus increasing the lenght of the protein, but mantaining the reading frame. Therefore, the variant was scored as de novo missense, rather than de novo variant. Furthermore, no functional evidence is available for this variant to determine if it results in loss of protein function. The short duplication variant is absent in gnomAD. The variant affects the Helicase ATP-binding domain, a mutational hotspot of the gene. 
High confidence in phenotypic quality. ASD diagnosis was determined based on behavioral assessment with the CARS and ABC, both evaluation tools have high rate of consistency with the DSM-IV criteria. ",0-1,0.0,0.5
39,Ohashi K et al. (2021): Comprehensive Genetic Analysis of Non-syndromic Autism Spectrum Disorder in Clinical Settings,33590427.0,ASD-097,DDX3X,: de novo,Variant is de novomissense,High confidence in phenotype,"ASD: The cases recruited in the study were diagnosed with ASD based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders criteria in the Nagoya City University Hospital. None of the parents of the patients were clinically diagnosed with ASD. All patients were evaluated by experienced and board certified child neurologists. Patients with dysmorphic facies or major anomalies were excluded from the study. Additional, inlcuded patients were assessed using the quotient of ASD with Childhood Autism Rating Scale (CARS)",g.41205861G>A,c.1601G>A,p.R534H,"Default score applied.
De novo missense variant identified through whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The variant is absent in gnomAD. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
40,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,DDX6,DDX3X,: de novo,Variant is de novomissense,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41203490-A,c.865-2A>G,,"Default score downgraded for genotypic evidence. 
De novo missense variant affecting a highly conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.25). The variant is absent in gnomAD, while it is reported on ClinVar as pathogenic.
High confidence in phenotypic quality. ",0-1,0.0,0.25
41,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,DDX7,DDX3X,: de novo,Variant is de novo,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41205860dupC,c.1600dup,p.R534Pfs*13,"Default score downgraded for genotypic evidence.
De novo nonsense mutation creating a premature stop codon in exon 10, thereby it is predicted to result in loss of protein function either due to the nonsense mediated mRNA decay or the formation of a truncated protein that lacks functional domains, in a gene in which haploinsufficiency is the known disease mechanism. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.5). The nonsense mutation is absent in gnomAD. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
42,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,DDX8,DDX3X,: de novo,Variant is de novomissense,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41200854dupG,c.269dup,p.S90Rfs*8,"Default score downgraded for genotypic evidence.
De novo missense variant affecting a highly conserved residue located within the Helicase ATP binding domain, which represents a mutational hostpot for the gene. In particular, the variant affects a residue involved in RNA binding. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.25). The variant is absent in gnomAD, while it is classified as pathogenic by reputable resources.
High confidence in phenotypic quality. ",0-1,0.0,0.25
43,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,DDX9,DDX3X,: de novo,Variant is de novomissense,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41205605A>T,c.1440A>T,p.R480S,"Default score downgraded for genotypic evidence. 
De novo in-frame deletion variant eliminating a conserved residue located within the Helicase ATP-binding domain. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.25). The variant is absent in gnomAD. 
High confidence in phenotypic quality. ",0-1,0.0,0.25
44,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,DDX11,DDX3X,: de novo,Variant is de novomissense,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41203500C>A,c.873C>A,p.Y291*,"Default score downgraded for genotypic evidence.
De novo in-frame deletion variant eliminating a single, highly conserved residue located within the Helicase APT-binding domain. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.25). Although the present case carries the same variant as a patient reported by Wang X, et al. (2018) PMID: 30349862 (Row: 126), the authors of the present study claimed that the current patient has not been published before. Thus, these two cases are unrelated. Indeed, this variant is a recurrent mutation detected in several cases with DDX3X syndrome. 
High confidence in phenotypic quality. ",0-1,0.0,0.25
45,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,"DDX12 (This case was previously reported by Lennox et al. (2020) PMID: 32135084. However, detail clinical information was not available for this patient in this former study)",DDX3X,: de novo,Variant is de novomissense,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41206189C>T,c.1693C>T,p.Q565*,"Default score downgraded for genotypic evidence.
De novo missense variant affecting a highly conserved residue located within the Helicase C-terminal domain, which represent a mutational hotspot. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.25). The non-synonymous variant is absent in gnomAD. 
High confidence in phenotypic quality. ",0-1,0.0,0.25
46,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,"DDX13 (This case was previously reported by Lennox et al. (2020) PMID: 32135084. However, detail clinical information was not available for this patient in this former study)",DDX3X,: de novo,Variant is de novo,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41203292G>C,c.766-1G>C,,"Default scored downgraded for genotypic evidence. 
De novo frameshift mutation creating a premature stop codon in exon 13, thus it is predicted to result in loss of protein function either due to the nonsense mediated mRNA decay or the formation of a truncated protein that lacks functional domains, in a gene in which haploinsufficiency is the known disease mechanism. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.5). The frameshift mutation is absent in gnomAD. 
High confidence in phenotypic quality.",0-2.5,2.0,1.5
47,Tang L et al. (2021): Prospective and detailed behavioral phenotyping in DDX3X syndrome,33993884.0,DDX15,DDX3X,: de novo,Variant is de novo,High confidence in phenotype,"ASD: The study performed a prospective, detailed phenotyping of a cohort of 15 patients with DDX3X syndrome focusing on behavioral, psychological and neurological symptoms. The cases were evaluated at the Seaver Autism Center in the Icahn School of Medicine at Mount Sinai. All participants were evaluated for a 3-4 day in-person visit at the Seaver Autism Center including approximately 9h of direct assessment, 6h of caregiver interviews, and 4h of caregiver questionnaires. All neuropsychological testing was completed by research-reliable clinical psychologists. Medical evaluations (psychiatric, neurologic, and clinical genetic) were completed by board-certified clinicians. A consensus diagnosis of ASD was determined using the DSM-5 criteria by psychiatric evaluation and based on the results from gold-standard diagnostic approaches including the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), and ADI-R. Caregiver questionnaires, including the Social Responsiveness Scale Second edition (SRS-2) and the Repetitive Behavior Scale-Revised (RBS-R) were used for further evaluate the ASD features",g.41205487delG,c.1321del,p.D441Ifs*3,"Default score downgraded for genotypic evidence.
De novo nonsense mutation creating a premature stop codon in exon 15. Although the abnormal stop codon is downstream of the functional domain of the protein, it likely triggers the nonsense mediated mRNA decay, thereby resulting in loss of function in a gene where haploinsufficiency is the known disease mechanism. Although the variant was detected in a certified clinical laboratory, the exact genotyping methods were not described in the study. For this reason, the score was downgraded (-0.5). The nonsense mutation is absent in gnomAD. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
48,Valentino F et al. (2021): Exome Sequencing in 200 Intellectual Disability/Autistic Patients: New Candidates and Atypical Presentations,34356170.0,Patient 11,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study investigated the underlying molecular causes in a cohort of 200 cases with diagnosis of ID and ID with ASD. The present case was diagnosed with ID and ASD. However, the criteria used to determine the diagnosis of ASD was not reported in the study",g.41205549dupA,c.1383dup,p.Y462Ifs*3,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through exome sequencing. The variant affects a highly conserved residue located within the Helicase ATP-binding domain. In particular, this residue is involved in RNA binding and is a recurrently mutated amino-acids in cases with DDX3X syndrome. Although the present case carries the same variant as a patient reported by Tang L. et al. (2021) PMID: 33993884 (Patient: DDX8; Row: 48), based on the clinical profile and age difference, it seems that these are unrelated patients. For this reason, the present case was also scored. This variant is absent in gnomAD, while reputable resources classified this variant as pathogenic. 
However, the score was downgraded due to low confidence in phenotypic quality (-0.25).",0-1,0.0,0.25
49,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2615-0,DDX3X,: de novo,Variant is de novo non-canonical splice site,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II score, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. Although formal diagnosis of ASD has not been determined for this case, her phenotype includes the presence of injurious behavior directed towards others, an ASD feature",g.41205589C>G,c.1423C>G,p.R475G,"Default score downgraded for phenotypic evidence.
De novo indel variant affecting the non-canonical donor splice site identified through clinical whole exome sequencing. The variant likely affects mRNA splicing resulting in loss of function in a gene in which haploinsufficiency is the known disease mechanism.
The variant is absent in gnomAD, while it is reported as pathogenic by ClinVar.
The score was downgraded due to low confidence in phenotypic quality (-0.5). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tool (SRS-II) indicated that the patient is above the ""at risk"" threshold for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1.5,1.0,0.5
50,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3179-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II score, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, formal diagnosis of ASD has not been established for this case so far",g.41204655A>G,c.1171-2A>G,,"Default score downgraded for phenotypic evidence.
De novomissense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a moderately conserved residue located within the Helicase ATP-binding domain, a mutation hotspot for the gene. In silico analysis predicted the variant as damaging, but no functional evidence is available. The variant is absent in gnomAD, while ClinVar classified this variant as likely pathogenic. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tool (SRS-II) indicated that the patient is above the ""at risk"" threshold for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
51,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2503-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). A formal diagnosis of ASD was determined in the case. Furthermore, based on the SRS-II and SCQ scores, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician",g.41345506,c.1271_1274,p.D425Nfs*9,"Default score downgraded for phenotypic evidence.
De novomissense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a moderately conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot.  
The variant is absent in gnomAD, while it is classified as pathogenic by LOVD. Functional evidence showed that the variant alters the function of the gene. However, since it is a recurrent mutation among cases with DDX3X, the score was not upgraded, to avoid overestimating the actual score for the gene.
The score was downgraded due to low confidence in phenotypic quality (-0.25). A formal diagnosis of ASD was determined in the present case, but behavioral phenotype was assessed using screening tools rather than gold-standard criteria. The screening tools indicated that the patient is above the ""at risk"" threshold for ASD risk. ",0-1,0.0,0.25
52,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 1090-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Although a formal diagnosis of ASD has not been determined in the case, assessment with the SRS-II and SCQ scores, indicated that the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician",g.38227303-42570649x3,,,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot for the gene. In particular, the affected amino-acid is involved in RNA binding. The variant is absent in gnomAD but it is a recurrent mutation detected in additional cases with DDX3X syndrome. Moreover, functional evidence supports the pathogenicity of the variant, showing that it results in complete loss of protein function. However, the score was not upgraded since it is a recurrent disease causing variant. This decision was made to avoid overestimating the actual score of the gene. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SRS-II and SCQ) indicated that the patient is above the ""at risk"" for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
53,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3437-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). In the present case ASD diagnosis has been established, but the methods used to determine the diagnosis were not reported",g.32210419-44428485x3,,,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot for the gene. In particular, the affected amino-acid is involved in RNA binding. The variant is absent in gnomAD but it is a recurrent mutation detected in additional cases with DDX3X syndrome. Moreover, functional evidence supports the pathogenicity of the variant, showing that it results in complete loss of protein function. However, the score was not upgraded since it is a recurrent disease causing variant. This decision was made to avoid overestimating the actual score of the gene. 
The score was downgraded due to low confidence in phenotypic quality. The case has received a formal diagnosis of ASD and her behavior is charcterized by stereotypies such as rocking and flapping. However, behavioral assessment was carried out only with screening tools rather than with gold standard criteria. Due to the lack of additional information regarding her socio-emotional behavior, the phenotypic quality was determined as low. ",0-1,0.0,0.25
54,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2839-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). A formal diagnosis of ASD was determined in the case. Furthermore, assessment with the SRS-II and SCQ scores, indicated that the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician",,c.11564delA,p.Y3855fs*22,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain. 
The variant is absent in gnomAD. On the other hand, this missense substitution is a recurrent mutation among cases with DDX3X syndrome. Furthermore, functional evidence supports the pathogenicity of the variant, indicating that the variant results in loss of function, consistent with the disease mechanism of the gene. However, the score was not upgraded to avoid overestimating the actual score. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). A formal diagnosis of ASD was determined in the present case, but behavioral phenotype was assessed using screening tools rather than gold-standard criteria. The screening tools indicated that the patient is above the ""at risk"" threshold for ASD risk. ",0-1,0.0,0.25
55,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3449-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). A formal diagnosis of ASD was reported in this case, but further assessment with the screening tools employed in the study was not carried out",,"c.11832dupC,c.11907dupC","p.A3943fs,p.Ser3945Gln,p.Ser3970Gln","Default score downgraded for phenotypic evidence.
De novo in-frame deletion variant identified through clinical whole exome sequencing. The indel variant eliminates a single, conserved residue located within the Helicase ATP-binding domain. The variant is absent in gnomAD. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). A formal diagnosis of ASD was reported in the case but further assessment with the screening tools employed in the study was not carried out. The methods used to determined the initial diagnosis of ASD were not reported in the study. ",0-1,0.0,0.25
56,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2575-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II score, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the present case so far",,c.2470T>G,p.S824A,"Default score downgraded for phenotypic evidence.
De novo in-frame deletion variant identified through clinical whole exome sequencing. The indel variant affects a single, highly conserved residue located within the Helicase-ATP binding domain. The variant is absent in gnomAD, while it is reported on ClinVar as pathogenic. Moreover, it is a recurrent mutation among cases with DDX3X syndrome. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SRS-II) indicated that the patient is above the ""at risk"" for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
57,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3151-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II score, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the present case so far",,,"p.G2704R,p.W963X","Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain. In silico analysis predicted the variant as damaging, but functional evidence is not available. The variant is absent in gnomAD, while ClinVar has conflicting interpretations of pathogenicity. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SRS-II) indicated that the patient is above the ""at risk"" for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
58,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2488-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). The case received a diagnosis of ASD",,c.8978A>G,p.Asn2993Ser,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a hihgly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. In silico analysis predicted the variant as damaging, functional evidence is not available. The variant is absent in gnomAD, while it is reported as pathogenic on LOVD. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). A formal diagnosis of ASD was reported in the case. The methods used to determined the initial diagnosis of ASD were not reported in the study. ",0-1,0.0,0.25
59,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3284-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II and SCQ scores, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the proband",g.33405505delC,c.823delC,p.P275Pfs,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The missense substitution affects a highly conserved residue located within the Helicase C-terminal domain. In silico analysis predicted the variant as damaging, but no functional evidence is available. The variant is absent in gnomAD, while it is reported as likely pathogenic by ClinVar.
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SRS-II and SCQ) indicated that the patient is above the ""at risk"" for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
60,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2577-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SCQ scores, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the proband",g.33400564C>T,c.490C>T,p.R164X,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The missense substitution affects a highly conserved residue located within the Helicase C-terminal domain. In silico analysis predicted the variant as damaging, but no functional evidence is available. The variant is absent in gnomAD. The variant affects a residue recurrently mutated among DDX3X patients.
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SCQ) indicated that the patient is above the ""at risk"" for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
61,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2497-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SCQ and SRS-II scores, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the proband",g.33419613-33419615CAG>C,c.3963_3964del,p.P1321fs,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The missense substitution affects a highly conserved residue located within the Helicase C-terminal domain. In silico analysis predicted the variant as damaging, but no functional evidence is available. The variant is absent in gnomAD. The variant affects a residue recurrently mutated among DDX3X patients.
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SCQ and SRS-II) indicated that the patient is above the ""at risk"" for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
62,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2872-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). A formal diagnosis of ASD was determined in the case. Furthermore, assessment with the SRS-II and SCQ scores, indicated that the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician",g.33403084T>C,,,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The missense substitution affects a highly conserved residue located within the Helicase C-terminal domain. In silico analysis predicted the variant as damaging, but no functional evidence is available. The variant is absent in gnomAD. The variant affects a residue recurrently mutated among DDX3X patients.
The score was downgraded due to low confidence in phenotypic quality (-0.25). A formal diagnosis of ASD was determined in the present case, but behavioral phenotype was assessed using screening tools rather than gold-standard criteria. The screening tools indicated that the patient is above the ""at risk"" threshold for ASD risk. ",0-1,0.0,0.25
63,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3039-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SCQ and SRS-II scores, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the proband",g.33411228C>T,c.2899C>T,p.Arg967X,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the C-terminal domain. In silico analysis predicted the variant as damaging, but functional evidence is not available. The variant is absent in gnomAD, while it is reported as likely pathogenic by ClinVar. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tools (SCQ and SRS-II) indicated that the patient is above the ""at risk"" threshold for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
64,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 2666-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II score, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the proband",g.33409384G>G,c.2142_2143insCC,p.L714fs,"Default score applied after modification for phenotypic and functional evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the C-terminal domain. In silico analysis predicted the variant as damaging. Reputable resources classified the variant primarily as pathogenic. Moreover, functional evidence showed that the variant resulted in mild impairment of protein activity, thus the score was upgraded (-0.25). The variant is absent in gnomAD. 
On the other hand, the score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tool (SRS-II) indicated that the patient is above the ""at risk"" threshold for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.5
65,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 1954-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). A formal diagnosis of ASD was determined in the case. Furthermore, assessment with the SRS-II and SCQ scores, indicated that the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician",g.33408650-33408652CTT>C,c.1822_1823del,p.F608fs,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The variant is absent in gnomAD, while reputable resources classified this variant as likely pathogenic. Functional evidence supports the pathogenicity of the variant showing that it resulted in complete loss of helicase activity, consistent with the disease mechanism of the gene. However, the score was not upraded since this is a recurrent mutation detected in additional patients with DDX3X syndrome. This decision was made to avoid overestimating the actual score of the gene. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). A formal diagnosis of ASD was determined in the present case, but the methods employed to determine the original diagnosis were not reported. Furthermore, behavioral assessment was conducted with screening tools, indicating that the patient is above the ""at risk"" threshold for ASD risk. ",0-1,0.0,0.25
66,Lennox AL et al. (2020):  Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development,32135084.0,Patient ID: 3072-0,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: This is the largest cohort of patients harbouring variants in the gene DDX3X. The behavioral profile of the cases was evaluated using a battery of assessments tools including the Vineland Adaptive Behavioral Scales (VABS), a standardized measure of child development, The Social Responsiveness Scale-II (SRS-II) and the Social Communication Questionnaire (SQC), which assessed risk for ASD and social impairment and The Child Behavior Checklist (CBC) to assess behavioral challenges. Based on these assessments, compared to neuroypical controls, patients had significant deviation in the mean score for all 3 exams (VABS, SRS-II and SCQ). Based on the SRS-II and SCQ score, the present case was above the ""at risk"" threshold for ASD and should be evaluated by a trained clinician. However, a formal diagnosis of ASD has not been determined in the proband",g.33391326G>A,c.G140A,p.R47Q,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through clinical whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The variant is absent in gnomAD, while reputable resources classified this variant as likely pathogenic. Functional evidence supports the pathogenicity of the variant showing that it resulted in complete loss of helicase activity, consistent with the disease mechanism of the gene. However, the score was not upraded since this is a recurrent mutation detected in additional patients with DDX3X syndrome. This decision was made to avoid overestimating the actual score of the gene. 
The score was downgraded due to low confidence in phenotypic quality (-0.25). Formal diagnosis of ASD has no been established for this case. However, behavioral assessment with the screening tool (SRS-II and SCQ) indicated that the patient is above the ""at risk"" threshold for ASD and further evaluation by a trained clinician is required. Since the patient's ASD profile was evaluated only through screening tools and not with standardized criteria, the phenotype quality was determined to be low.",0-1,0.0,0.25
67,"Guo H, et al. (2018): Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model",30564305.0,HN0072.p1,DDX3X,: de novo,Variant is de novo canonical splice site,High Confidence in Phenotype ,ASD: The proband is part of the Autism Clinical and Genetics Resources in China (ACGC). Clinical diagnosis was ascertained according to the DSM-IV criteria. Additional tools used to evaluate autisitic features included the Social Responsiveness Scale (SRS),g.334122222A>A,,,"Default score downgraded for genotypic evidence.
De novo variant affecting the canonical acceptor splice site, identified through targeted sequencing of 187 autism risk genes using single molecule molecular inversion probes. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The splice variant is absent in gnomAD, while it is reported as pathogenic by LOVD. It is a recurrent mutation among cases with DDX3X syndrome. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
70,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 3 (This case was also reported in the Deciphering Developmental Disorder Study et al. (2015) PMID: 25533962),DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33403326G>A,c.G698A,p.C233Y,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot. The variant is absent in gnomAD. On the other hand, this missense substitution is a recurrent mutation among cases with DDX3X syndrome. Furthermore, functional evidence supports the pathogenicity of the variant, indicating that the variant results in loss of function, consistent with the disease mechanism of the gene. However, the score was not upgraded to avoid overestimating the actual score. 
However, the score was downgraded due to low confidence in phenotypic quality (-0.25). ",0-1,0.0,0.25
71,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 5 (This case was also reported in the Deciphering Developmental Disorder Study et al. (2015) PMID: 25533962),DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33408650-33408652CTT>C,c.1822_1823del,p.F608fs,"Default score applied after modification for phenotypic and functional evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. In particular, the affected amino-acid is involved in ATP-binding. The variant is absent in gnomAD, while reputable resources classified the variant as pathogenic. In silico analysis predicted the variant as damaging. Furthermore, functional studies showed that the variant results in lss of protein function, consistent with the disease mechanism of the gene. Therefore, based on the functional evidence, the score was upgraded (+0.25).
However, the score was downgraded due to low confidence in phenotypic quality (-0.25).",0-1,0.0,0.5
72,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 15,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33414451-33414455GAACA>G,c.3683_3686del,p.E1228fs,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The missense substitution is absent in gnomAD. in silico analysis predicted the variant as damaging, but no functional evidence is available for this variant. 
The score was downgraded for low confidence in the phenotypic quality (-0.25).",0-1,0.0,0.25
73,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 26,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33411159G>A,c.G2830A,p.G944S,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot. The missense substitution is absent in gnomAD, while its classification is not consistent among different databases. No functional evidence is available regarding the effect of this variant on protein function. 
The score was downgraded due to low confidence in the phenotypic quality (-0.25).",0-1,0.0,0.25
74,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 29,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33411159G>A,c.G2830A,p.G944S,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain. The variant is absent in gnomAD. On the other hand, this missense substitution is a recurrent mutation among cases with DDX3X syndrome. Furthermore, functional evidence supports the pathogenicity of the variant, indicating that the variant results in loss of function, consistent with the disease mechanism of the gene. However, the score was not upgraded to avoid overestimating the actual score. 
On the other hand, the score was downgraded due to low confidence in phenotypic quality (-0.25)",0-1,0.0,0.25
75,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 30,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33408650-33408652CTT>C,c.1822_1823del,p.F608fs,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The missense substitution is absent in gnomAD, but it is reported as pathogenic by LOVD. In silico analysis predicted the variant as damaging but functional evidence is not available. 
The score was downgraded due to low confidence in the phenotypic quality (-0.25).",0-1,0.0,0.25
76,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 31,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33403326G>A,c.G698A,p.C233Y,"Default score downgraded for phenotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-binding domain, which represents a mutational hotspot.  
The variant is absent in gnomAD, while it is classified as pathogenic by LOVD. Functional evidence showed that the variant alters the function of the gene. However, since it is a recurrent mutation among cases with DDX3X, the score was not upgraded, to avoid overestimating the actual score for the gene.
The score was downgraded due to low confidence in the phenotypic quality (-0.25).",0-1,0.0,0.25
77,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,Individual 35,DDX3X,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression were present in 20/38 female carries of de novo mutations in DDX3X. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed by each clinical center for the establishment of the ASD diagnosis were reported",g.33400029G>A,c.G387A,p.S129S,"Default score applied after modification for phenotypic and genotypic evidence.
De novo missense variant identified through trio-based whole exome sequencing. The variant affects a highly conserved residue located within the Helicase C-terminal domain, which represents a mutational hotspot. The missense substitution is absent in gnomAD, but it is reported as pathogenic by reputable resources. Functional evidence showed that the variant reduces the activity of the protein, thus the score was upgraded (+0.25).
On the other hand, the score was downgraded due to low confidence in the phenotypic quality (-0.25).",0-1,0.0,0.5
78,"Snijders Blok L, et al. (2015): Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling",26235985.0,"Family 1, Individual A",DDX3X,": Maternally Inherited (The carrier mother is unaffected mainly due to skewed X-inactivation of the mutant allele >95%). This variant segregated in this family, detected in 2 affected brothers and one maternal uncle. All of them affected. Therefore, the variant co-segregated with the phenotype in this family.",Other variant type not predicted/proven null (not de novo),Low Confidence in Phenotype,"ASD: The study performed Whole exome sequencing analysis in cases with unexplained ID, due to the lack of molecular diagnosis by previous molecular testing. Complete clinical details were obtained from a cohort of 38 females and 3 families carrying variants in DDX3X, from different cohorts following the relevant institutions and national guidelines and regulations. The neurodevelopmental phenotype associated with variants in DDX3X was characterized. Behavioral problems including autism spectrum disorder, hyperactivity and aggression was present in the cases from this family. However, diagnosis of ASD was not systematically evaluated in this study and no description of the methods employed to determine the diagnosis of ASD were described",g.33391308G>A,c.G122A,p.R41H,"Default score downgraded for phenotypic evidence.
Maternally inherited missense variant identified through trio-based whole exome sequencing. The non-synonymous variant affects a highly conserved residue located within the Helicase ATP-bidning domain. The carrier mother is unaffected, possibly explained by her skewed X-inactivation pattern. On the other hand, the variant co-segregated with the disease phenotype in additional affected family members. The variant is absent in gnomAD, while it is reported as pathogenic by reputable resources. Functional evidence provided in this study did not find a detrimental effect of the variant on protein function, at least on the activity of the gene in the Wnt pathway. Based on all this evidence, the variant was scored under the criteria of other variant type not predicted/proven null, due to lack of functional evidence, but the score was upgraded since the variant co-segregated with the disease phenotype (+0.1).
On the other hand, the variant was downgraded due to low confidence in phenotypic quality (-0.1).",0-0.1,0.0,0.1
80,Chandrasekhar A et al. (2023): Genome sequencing detects a balanced pericentric inversion with breakpoints that impact the DMD and upstream region of POU3F4 genes,37929330.0,Case report Index patient,DMD,: Maternally Inherited (The mother is,Variant is predicted/Proven null ,Low Confidence in Phenotype ,"ASD: The index patient was diagnosed with autism spectrum disorder and muscular dystrophy. However, the diagnostic methods/criteria used to determined the ASD diagnosis were not reported in the study",,c.556_557delCT,p.Leu186fs,"Default score downgraded for genotypic and phenotypic evidence. 
Maternally inherited structural variant (SV) identified through clinical whole genome sequencing and further experimentally validated by orthogonal methods. The SV is a 50Mb pericentric inversion disrupting the DMD gene. The breakpoint of the short arm is located within intron 55 of DMD, thus, it is predicted to result in premature transcription termination and nonsense mediated decay. Experimental analysis confirmed that absence of dystrophin protein expression in muscle biopsy. Further supporting that the SV impairs the DMD gene. Although the inversion spans 50Mb containing many genes, the structural variant results in a balance rearrangement. Therefore, the involvement of additional genes is minimal but it cannot be rule out. Consequently, the SV was scored, assessed under the criteria of variant predicted/proven null, but a downgrade was applied (-0.5). No intragenic inversion are reported in gnomAD. On the other hand, the only clinically significant gene impaired by the SV is the POU3F4, a gene implicated in genetic hearing loss. However, the gene has not been associated with ASD risk. The disruption of the regulatory region of this gene explains the sensorineural hearing loss observed in the patient. Furthermore, the variant was also detected in the affected half-brother, who presented a similar clinical profile, supporting that the variant co-segregated with the phenotype in the family.
The score was further downgraded for low confidence in phenotypic quality (-0.5) ",0-2,1.0,0.5
82,Folland C et al. (2023): Transcriptome and Genome Analysis Uncovers a DMD Structural Variant: A Case Report,37090938.0,Single case report,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The case was diagnosed with ASD, but the criteria and psychological tools used to assess the phenotype of the patient were not reported. However, the clinical profile of the case is consistent with the main features of ASD including poor social interactions, lack of interactive play",,c.3G>T,p.Met1Ile,"Default score downgraded for genotypic and phenotypic evidence. 
Structural variant of unknown inheritance identified through targeted, long-read sequencing of a customized muscle-disease gene panel. Although the exact number of genes included in the panel was not specified, the score was not downgraded since the patient also underwent additional genome-wide molecular analysis. The structural variant resulted in a paracentric inversion due to microhomology between 2 transposons. This 216Kb inversion encompasses the promoters and the first coding exons of the cortical isoform (Dp427c), which is expressed in the brain, and the skeletal muscle isoform (Dp427m). Loss of expression of the dystrophin protein, in the skeletal muscle, was confirmed by experimental analysis. Confirming that the inversion leads to loss of function. Therefore, the variant is consistent with the disease mechanism of the gene, mediated by hemizygous loss of function. No intragenic inversion are reported in gnomAD. On the other hand, through the additional molecular testing, a CGG repeat expansion in the 5'UTR region of the gene DIP2B was detected. This repeat expansion has been associated with autosomal dominant intellectual developmental disorder. Although the gene has not been associated with ASD risk, this variant might modulate the phenotypic expression of the patient. Consequently, the score was downgraded (-0.5). 
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
83,"Passos-Bueno MR, et al. (2022): Dystrophin genetic variants and autism",37861890.0,Patient 1 Family 1,DMD,: Maternally Inherited (The variant was also detected in the unaffected monozygotic twin sibling),Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: Diagnosis of ASD was determined by a neurologist at the age of 7 years-old. The assessment tools included ADOS (23 points) and CARS (35 points), whose results were compatible with mild to moderate ASD diagnosis",,,,"Default score downgraded for genotypic evidence.
Maternally inherited CNV loss identified through whole exome sequencing and validated by MLPA analysis. The variant contains exons 2-9. A shorter deletion containing exons 3-9 was reported in gnomAD, observed in male individuals. Since different deletions with distinct exon content can lead to different effects in the transcript, the variant was slightly downgraded (-0.25). The deletion was also inherited by the monozygotic twin brother. However, the sibling showed a remarkably different clinical profile, with normal development and no diagnosis of ASD, since he did not meet the criteria cut-off. Therefore, the variant is likely incompletely penetrant or additional genetic contributions could explain the difference in phenotypic expression. Furthermore, an additional clinically significant variant was also detected in both siblings, which was inherited from the unaffected father. Although the gene is associated with brain abnormalities and neurodegeneration, the gene has not been implicated in ASD risk, based on SFARI. On the other hand, the condition of the CSF1R gene in inherited in autosomal recessive pattern. Due to the lack of co-segregation of the DMD variant with the ASD phenotype and the identification of the additional pontentially relevant variant, the score was downgraded (-0.5)
High confidence in phenotypic quality. ",0-2,1.0,0.75
84,"Passos-Bueno MR, et al. (2022): Dystrophin genetic variants and autism",37861890.0,Patient 3; Family 2,DMD,: Maternally Inherited,Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: Diagnosis of high-functioning ASD was determined by a neurologist using the DSM-IV or 5 criteria. Furthermore, the clinical profile of the patient is consistent with the main features of ASD including stereotypies, echolalia, no interaction and absent eye contact",,c.1003C>T,p.Arg335*,"Default score downgraded for genotypic evidence.
Maternally inherited nonsense mutation identified through whole exome sequencing. The variant is predicted to create a premature stop codon in exon 78, the penultimate exon of the gene, affecting only the last 5 amino-acids of the protein. Therefore, it is unlikely to trigger the nonsense mediated mRNA decay pathway. However, functional evidence is not available to support this prediction while the actual effect is unknown. The variant is observed in gnomAD including male individuals and ClinVar reported the variant as VUS. Due to the lack of evidence supporting its pathogenicity (-0.5) and the presence in healthy individuals (-0.5) the score was downgraded. Furthermore, an additional clinically significant variant was also retected in the patient. Although the variant has not been implicated in ASD etiology, the variant is associated with AD late-onset dementia. The contribution of this variant cannot be rule out, thus the score was slightly downgraded (-0.25)
High confidence in phenotypic quality. ",0-2,1.0,0.25
85,"Passos-Bueno MR, et al. (2022): Dystrophin genetic variants and autism",37861890.0,Patient 4; Family 3,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: Diagnosis of ASD was determined at the age of 6 years of age, the case scored 32.5 by the CARS autism scale, which is compatible with ASD diagnosis. Diagnosis was determined by a neurologist based on the DSM IV or 5 criteria",,c.494G>T,p.Gly165Val,"Default score applied.
Out of frame deletion variant of unknown inheritance identified through whole exome sequencing. The variant results in the deletion of 22 base pairs and is predicted to affects all full length isoforms but not the shorter isoforms. The variant is absent in gnomAD. No additional variants were detected in the proband. Furthermore, the variant was also detected in the 2 affected non-identical twin brothers, who were also diagnosed with ASD. Therefore, the variant co-segregated with the phenotype in the family. 
High confidence in phenotypic quality. ",0-2,1.0,1.5
88,"Noda S, et al. (2021): Duchenne Muscular Dystrophy Successfully Treated with Aripiprazole in a Patient with Autism Spectrum Disorder Symptoms Including Irritability",34148958.0,Case report,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: Initially the case was diagnosed with pervasive developmental disorder determined by a psychiatrist. Then, assessment with the DSM-5 criteria confirmed the diagnosis of ASD",,c.385G>A,p.Gly129Arg,"Default score downgraded for genotypic evidence.
Frameshift mutation of unknown inheritance identified through targeted sequencing of the DMD coding gene. Due to the targeted sequencing approach, the score was downgraded (-0.5). The study only reported that the variant resulted in a frameshift in exon 70. However the genomic coordinates and nature of the frameshift was not reported. Therefore, it was not possible to compare with gnomAD variants (-0.5).
High confidence in phenotypic quality. ",0-2,1.0,0.5
90,Tran KT et al. (2020): Genetic landscape of autism spectrum disorder in Vietnamese children,32193494.0,ASD057,DMD,: Maternally Inherited,Other variant type not predicted/proven null (not de novo),High Confidence in Phenotype,"ASD: Proband received a definite diagnosis of ASD. Proband was evaluated with the Autism Diagnostic Observation Schedule (Score = 20/12) and the Childhood Autism Rating Scale (Score = 48). Developmental level was determined with the Denver II scale which assessed 5 domains, including ""personal-social"", ""fine motor"", ""gross motor"", ""Understanding"" and ""Language"". Official diagnosis of ASD was ascertained according to the DSM-5 criteria",,c.386_387del,p.Gly129Val,"Default score applied.
Maternally inherited missense variant identified through trio based Whole Exome sequencing and validated by Sanger sequencing. The variant is absent in gnomAD and affects a highly conserved residue located within the spectrin repeat domain. In silico analysis predicted that the variant is moderately damaging but no functional evidence is available for this variant.
High confidence in phenotypic quality.",0-0.1,0.0,0.1
91,Tran KT et al. (2020): Genetic landscape of autism spectrum disorder in Vietnamese children,32193494.0,ASD059,DMD,: de novo,Variant is de novomissense,High Confidence in Phenotype,"ASD: Proband received a definite diagnosis of ASD. Proband was evaluated with the Autism Diagnostic Observation Schedule (Score = 21/12) and the Childhood Autism Rating Scale (Score = 46). Developmental level was determined with the Denver II scale which assessed 5 domains, including ""personal-social"", ""fine motor"", ""gross motor"", ""Understanding"" and ""Language"". Official diagnosis of ASD was ascertained according to the DSM-5 criteria",,c.1003C>T,p.Arg335*,"Default score applied.
De novomissense variant identified through trio based Whole Exome sequencing and validated by Sanger sequencing. The variant is absent in gnomAD and affects a highly conserved residue located within the binding/rhoptry protein domain. In silico analysis predicted that the variant is moderately damaging but no functional evidence is available for this variant.
High confidence in phenotypic quality.",0-1,0.0,0.5
93,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 1,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.728delT,p.Phe243fs,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV loss of unknown inheritance identified through MLPA analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The deletion contained the exons 10-29. However, the precise breakpoints were not specified in the study. A larger CNV loss is reported in gnomAD, but this deletion was only observed in 2 females. Therefore, the CNV loss is consistent with the disease mechanism of the gene medited by hemizygous loss of function variants.
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.75
94,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 2,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.475A>G,p.Argl59Gly,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV loss of unknown inheritance identified through MLPA analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The deletion contained the exons 42-45. However, the precise breakpoints were not specified in the study. No CNV deletion containing these exons have been reported in gnomAD. 
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.75
95,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 3,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.388C>T,p.Arg130*,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV loss of unknown inheritance identified through Multiplex PCR analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The deletion contained the exons  43-44. However, the precise breakpoints were not specified in the study. No intragenic CNV deletion, reported in gnomAD, contains exon 44.
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.75
96,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 4,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.610C>G,p.Pro204Ala,"Default score downgraded for genotypic evidence.
Intragenic CNV loss of unknown inheritance identified through MLPA analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The deletion contained the exons 45-52 . However, the precise breakpoints were not specified in the study. A larger deletion encompassing exons 45-55 was detected in gnomAD, observed in single hemizygous male. However, since different deletions results in out-of-frame or in-frame effects, the score was slightly downgraded (-0.25)
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.5
97,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 5,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.390G>A,,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV gain of unknown inheritance identified through MLPA analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The duplication contained the exons 18-41. However, the precise breakpoints were not specified in the study. No CNV gain containing similar exons is reported in gnomAD. Although the variant results in the duplication of internal exons, dystrophin expression analysis showed that the variant leads to absent protein expression. However, the score was not upgraded since the analysis was performed using muscle biopsy samples. But this evidence supported that the variant results in loss-of-function.
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.75
98,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 6,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.634+2T>G,,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV loss of unknown inheritance identified through direct DMD sequencing. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The deletion contained the exon 45. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 45-55 was observed in a single male in gnomAD. However, no deletion containing exclusively exon 45 has been observed in gnomAD. Since different deletions with distinct exon content can lead to different effects in the transcript, the variant was slightly downgraded (-0.25).
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.5
99,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 7,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.39_41delAAG,,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV loss of unknown inheritance identified through MLPA analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The deletion contained the exons 45-50. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 45-55 was observed in a single male in gnomAD. Since different deletions with distinct exon content can lead to different effects in the transcript, the variant was slightly downgraded (-0.25).
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.5
100,Fujino et al. (2018): Autism spectrum disorders are prevalent among patients with dystrophinopathies,29594829.0,Patient 8,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: The goal of the study was to determine the prevalence of autism spectrum disorder (ASD) among cases with dystrophinopathies in a Japanese population. The patients included in the study were recruited from the muscular dystrophy outpatient clinic of Toneyama National Hospital. Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinical rating scale. The PARS is a semi-structured interview that assesses autistic symptoms and behaviours defined in the Diagnostic and Statistical Manual (fourth edition, text revision) based on information provided by caregivers. Patients who scored above the threshold for ASD in the infantile and current rating were classified as ASD. From this cohort, 11 patients (19.6%) met the criteria for ASD based on the infantile and current ratings of the PARS. Of these 11 patients, only 2 had recevied a formal diagnosis of ASD from their paediatrician or paediatric psychiatrist before the present study; the remaining nine had not previously undergone a comprehensive assessment for neurodevelopmental disordersThe study revealed that there was a high prevalence of ASD in patients with dystrophinopathies",,c.75G>T,p.Leu25Phe,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic CNV gain of unknown inheritance identified through MLPA analysis. Given the limited resolution and targeted genotyping approach, the score was downgraded (-0.5). The duplication contained the exons 8-51. However, the precise breakpoints were not specified in the study. No CNV duplication containing the same exons has been reported in gnomAD. Although intragenic CNV duplications have been detected in a subset of patients with DMD, no functional evidence is available regarding the effect of this variant. Therefore, the score was downgraded (-0.5)
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). Autistic symptoms were evaluated using the PARS scale, a common ASD screening tool developed in Japan for pervasive developmental disorders. However, other, gold-standard tools were not employed",0-2,1.0,0.25
114,"Ricotti V, et al. (2015): Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system",26081639.0,Patient 6,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The patient was recruited from the neuromuscular outpatient Department at Great Ormond Street Hospital (GOSH). The case has a molecularly confirmed diagnosis of Duchenne muscular dystrophy by the identification of an out-of-frame mutation in the DMD gene. The Social and Communication Disorders Checklist (SCDC) was completed by the patient's family. The SCDC is a validated measure for neurodevelopmental disorders. A total score of >8 is indicative of neurodevelopmental disturbances, especially in the social communication domain. On the other hand, scores >15 are strongly suggestive of Autistic Spectrum Disorder (ASD). The SCDC score of the current patient is 16. Additionally, the present case was further assessed with the Developmental, Diagnostic and Dimensional Interview short version (3Di-sv) to further confirmed the diagnosis of ASD. The 3Di-sv provides a brief standardized parental interview for diagnosis of ASD. The case met the threshold scores for ASD under this criteria. Other assessment tools included the Conners Parent Rating Scale (Conners 3) to assess Attention Deficit Hyperactivity Disorder (ADHD); and the Child and Behavioural Check List (CBCL) to assess internalising and externalising emotional problems",g.89692790G>A,c.C988T,p.D92N,"Default score downgraded for genotypic and phenotypic evidence. 
CNV loss of unknown inheritance identified through MLPA analysis or direct sequencing of the 79 exons and adjacent exon/intron boundaries. The exact breakpoints of the deletion were not reported. Therefore, due to the limited resolution of the genotypic methods, and the lack of precise breakpoints, the score was downgraded (-0.5). The CNV deletion contains exons 8-13 of the larger isoform including the cortically expressed isoform (Dp427c). No deletion containing the same exons are reported in gnomAD. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
116,Gazzellone et al. (2014): Copy number variation in Han Chinese individuals with autism spectrum disorder,25170348.0,567-3,DMD,: de novo,Variant is de novo,High Confidence in Phenotype,"ASD: The families were referred to the Children Development and Behavior Research Center (CDBRC) at Harbin Medical University, China, by their community physician. The Autism Behavior Checklist (ABC) and Childhood Autism Rating Scale (CARS) were used for diagnosis. The diagnosis of ASD was determined by two psychiatrists at the CDBRC",,c.388C>T,p.Arg130*,"Default score downgraded for genotypic evidence.
De novo CNV loss identified through micro-array analysis performed in trio. Given the limited resolution of the genotyping methods, the score was downgraded (-0.5). The 154Kb deletion contains exons 45-50 of the larger isoform, including the cortically expressed isoform (Dp427c). Although a larger CNV loss was observed in a male individual in gnomAD, this deletion contains additional exons. Different intragenic deletions, containing different exons can lead to in-frame or out of frame transcripts, resulting in different effects on protein function. The patient's variant is consistent with the disease mechanism of the gene, mediated by hemizygous loss of function. Therfore, the score was not downgraded.
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
117,Gazzellone et al. (2014): Copy number variation in Han Chinese individuals with autism spectrum disorder,25170348.0,611-3,DMD,: de novo,Variant is de novo,High Confidence in Phenotype,"ASD: The families were referred to the Children Development and Behavior Research Center (CDBRC) at Harbin Medical University, China, by their community physician. The Autism Behavior Checklist (ABC) and Childhood Autism Rating Scale (CARS) were used for diagnosis. The diagnosis of ASD was determined by two psychiatrists at the CDBRC",,c.737C>T,p.Pro246Leu,"Default score downgraded for genotypic evidence.
De novo CNV loss identified through micro-array analysis performed in trio. Given the limited resolution of the genotyping methods, the score was downgraded (-0.5). The 55Kb deletion contains exons 14-17 of the larger isoform, including the cortically expressed isoform (Dp427c). Although a similar CNV loss was observed in gnomAD, this deletion was only detected in a female individual. Furthermore, different intragenic deletions, containing different exons can lead to in-frame or out of frame transcripts, resulting in different affects on protein function. The patient's variant is consistent with the disease mechanism of the gene, mediated by hemizygous loss of function. Therfore, the score was not downgraded.
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
119,"Imbornoni L, et al. (2014): Diagnostic and clinical characteristics of early-manifesting females with Duchenne or Becker muscular dystrophy.",25125379.0,Patient 9,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The study investigated the clincial manifestation observed in females carriers of DMD mutations, with a focus on cognitive and mental health disorders. Female heterozygotes of dystrophinopathy were identified through the Muscular Dystrophy Surveillance Tracking and Research Network, a multisite population-based surveillance system supported by the Centers for Disease Control and Prevention. A systematic clinical assessment was not performed in the study, but clinical data was retrospectively obtained from medical records. The clinical description of the present case includes autistic features. However, methods used to assess the autistic symptoms were not documented in the study",,c.420_421insA,p.H141Tfs*39,"Default score downgraded for genotypic and phenotypic evidence. 
CNV gain of unknown inheritance spanning exons 45-55 of the DMD gene. The genotyping methods were not reported in the study (-0.5). The exact CNV breakpoints were not specified complicating the comparison with gnomAD variants. However, a similar CNV gain has been observed in gnomAD, but only detected in a single male individual (-0.25). Although in general heterozygous female of DMD mutations are unaffected, several studies have reported that some carriers present symptoms associated with dystrophinopathies. 
Finally, the score was downgraded for low confidence in phenotypic quality (0.5). ",0-2,1.0,0.25
122,"Kenny EM, et al. (2013): Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders",24126926.0,,DMD,: Unknown Inheritance,Variant is of unknown inheritance canonical splice site,High Confidence in Phenotype,"ASD: The ASD patients were recruited through schools, parent support groups and clinician referral with local ethics approval. Autism diagnoses were confirmed using the Autism Diagnostic Interview-Revised and the Autism Diagnostic Observation Schedule-Generic. Autism symptoms severity was determined using the ADOS severity metric, adaptive functioning using the Vineland Adaptive Behavior Composite - Standard Score (ABC-SS) and verbal status as determined by the ADI-R",g.89692908C>T,"c.C392T,c.C911T","p.T131I,p.T304I","Default score downgraded for genotypic evidence. 
Canonical donor splice variant of unknown inheritance identified through next generation targeted sequencing of 215 candidate genes involved in synaptic function and neurodevelopment. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The variant is observed in gnomAD in both males and females (-0.5). Furthermore, the variant is reported by reputable resources with conflicting interpretations of pathogenicity, but most of the evidence supports a benign effect. If the variant affects the splice site, it would lead to a cryptic stop codon. However, in silico tools predicted that the variant acutally strengthen the canonical donor site. However, no functional evidence is available to determined the actual impact of the variant. But since most of the evidence suggest that the variant might not affect splicing, the score was slightly downgraded (-0.25) 
High confidence in phenotypic quality.",0-2,1.0,0.25
123,"Daoud F, et al (2009): Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression",19602481.0,4119,DMD,: Maternally Inherited,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The study reported the clinical, cognitive, molecular and expression data on a cohort of 81 DMD/BMD patients with mutations predicted to affect either all dystrophin products including Dp71 or all dystrophin products except Dp71. Then, performed genotype-phenotype correlations to determine the effect of specific mutations disease severity. The clinical description of the case included autistic behavior. However, the specific ASD features were not reported nor the methods employed to assess the behavior of the patient",,c.353A>C,p.H118P,"Default score downgraded for genotypic and phenotypic evidence.
Materanlly inherited intragenic CNV loss affecting exons 55-77 of the DMD gene. The genotyping methods used to detect the variant were not documented in the study. Therefore, the score was downgraded (-0.5). No CNV deletion affecting the same exons have been reported in gnomAD. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
124,"Daoud F, et al (2009): Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression",19602481.0,LD205,DMD,: Maternally Inherited,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The study reported the clinical, cognitive, molecular and expression data on a cohort of 81 DMD/BMD patients with mutations predicted to affect either all dystrophin products including Dp71 or all dystrophin products except Dp71. Then, performed genotype-phenotype correlations to determine the effect of specific mutations disease severity. The clinical description of the case included autistic behavior. However, the specific ASD features were not reported nor the methods employed to assess the behavior of the patient",,c.530A>G,p.Y176C,"Default score downgraded for genotypic and phenotypic evidence.
Maternally inherited nonsense mutation predicted to create a premature stop codon in exon 70 of the DMD gene. However, the genotyping methods used to detect the variant were not documented in the study. Therefore, the score was downgraded (-0.5). The nonsense variant is absent in gnomAD. Expression analysis confirmed that the variant resulted in absent dystrophin product. 
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
125,"Daoud F, et al (2009): Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression",19602481.0,3466,DMD,: Maternally inherited,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The study reported the clinical, cognitive, molecular and expression data on a cohort of 81 DMD/BMD patients with mutations predicted to affect either all dystrophin products including Dp71 or all dystrophin products except Dp71. Then, performed genotype-phenotype correlations to determine the effect of specific mutations disease severity. The clinical description of the case included autistic behavior. However, the specific ASD features were not reported nor the methods employed to assess the behavior of the patient",,c.824A>G,p.N276S,"Default score downgraded for genotypic and phenotypic evidence.
Maternally inherited nonsense mutation predicted to create a premature stop codon in exon 70 of the DMD gene. However, the genotyping methods used to detect the variant were not documented in the study. Therefore, the score was downgraded (-0.5). The nonsense variant is absent in gnomAD. Expression analysis confirmed that the variant resulted in absent dystrophin product. 
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
126,"Young HK, et al. (2007): Cognitive and psychological profile of males with Becker muscular dystrophy",18056690.0,Patient 23,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: Assessment of the behavioral and emotional phenotype was determined with the Child Behavior Checklist, which was completed by the parents. This is a common screening tool to help with the ASD diagnosis",,,,"Default score downgraded for genotypic evidence.
CNV loss of unknown inheritance identified through PCR analysis or MLPA of the dystrophin gene. Given the targeted and low resolution of the genotyping strategy, the score was downgraded (-0.5). The exact breakpoints of the deletion was not defined, but the CNV encompassess exons 45-47. A larger deletion has been observed in gnomAD detected in a hemizygous male. Due to the lack of precise breakpoints and overlapping CNVs in gnomAD, the score was further downgraded (-0.25). 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.25
127,"Wu JY, et al. (2006): Association of Duchenne muscular dystrophy with autism spectrum disorder",16417872.0,Patient 1,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: Diagnosis of autism spectrum disorder/pervasive developmental disorder was determined by a pediatric neurologist in agreement with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Criteria,,,,"Default score upgraded after modification for genotypic and functional evidence.
CNV loss of unknown inheritance identified by polymerase chain reaction analysis (PCR). Due to the targeted approach and limited resolution of the genotyping methods, the score was downgraded (-0.5). However, through muscle biopsy analysis, it was determined that the patient has no dystrophin expression, supporting that the mutation detected in the patient leads to hemizygous loss of function, which is the known disease mechanism for the gene. For this reason, the variant was assessed under the criteria of predicted/proven null. The exact breakpoints of the deletion were not defined, challenging the comparison with variants reported in gnomAD, thus the score was slightly downgraded (-0.25).  A larger CNV deletion overlapping with the patient's CNV was observed in gnomAD, but it was detected in a single female. Since females are generally unaffected carriers, the score was not modified. On the other hand, functional evidence from a mouse model carrying a deletion of exon 52 showed that this variants results in lack of expression of the brain expressed Dp140 isoform. The mutant mice exhibited ASD-like behaviors including aberrant social interactions and repetitive behaviors. These ASD-like behaviors were ameliorated by partial rescue of the isoform. Based on the subtantial functional evidence, the score was upgraded (+1)
High confidence in phenotypic quality. ",0-2,1.0,1.75
128,"Wu JY, et al. (2006): Association of Duchenne muscular dystrophy with autism spectrum disorder",16417872.0,Patient 4,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: Diagnosis of autism spectrum disorder/pervasive developmental disorder was determined by a pediatric neurologist in agreement with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Criteria,,,,"Default score downgraded for genotypic evidence.
CNV loss of unknown inheritance identified by polymerase chain reaction analysis (PCR). Due to the targeted approach and limited resolution of the genotyping methods, the score was downgraded (-0.5). Through muscle biopsy analysis, it was determined that the patient has no dystrophin expression, supporting that the mutation detected in the patient leads to hemizygous loss of function, which is the known disease mechanism for the gene. However, the score was not upgraded since the analysis was performed using muscle biopsy samples. But this evidence supported that the variant results in loss-of-function. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 45-55 was observed in a single male in gnomAD. However, no deletion containing exclusively exon 45 has been observed in gnomAD. Since deletions with different exon content can lead to different effects in the transcript, the variant was slightly downgraded (-0.25).
High confidence in phenotypic quality. ",0-2,1.0,0.75
129,"Wu JY, et al. (2006): Association of Duchenne muscular dystrophy with autism spectrum disorder",16417872.0,Patient 6,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: Diagnosis of autism spectrum disorder/pervasive developmental disorder was determined by a pediatric neurologist in agreement with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Criteria,,,,"Default score downgraded for genotypic evidence.
CNV loss of unknown inheritance identified by polymerase chain reaction analysis (PCR). Due to the targeted approach and limited resolution of the genotyping methods, the score was downgraded (-0.5). However, through muscle biopsy analysis, it was determined that the patient has no dystrophin expression, supporting that the mutation detected in the patient leads to hemizygous loss of function, which is the known disease mechanism for the gene. However, the score was not upgraded since the analysis was performed using muscle biopsy samples. But this evidence supported that the variant results in loss-of-function. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 45-55 was observed in a single male in gnomAD. Although CNV deletions with different exon content result in distinct effects in the transcript, due to the considerable overlap between the CNV loss in gnomAD and the patient's CNV, the score was downgraded (-0.5)
High confidence in phenotypic quality. ",0-2,1.0,0.5
130,"Wu JY, et al. (2006): Association of Duchenne muscular dystrophy with autism spectrum disorder",16417872.0,Patient 7,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: Diagnosis of autism spectrum disorder/pervasive developmental disorder was determined by a pediatric neurologist in agreement with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Criteria,,,,"Default score downgraded for genotypic evidence.
CNV loss of unknown inheritance identified by polymerase chain reaction analysis (PCR). Due to the targeted approach and limited resolution of the genotyping methods, the score was downgraded (-0.5). However, through muscle biopsy analysis, it was determined that the patient has no dystrophin expression, supporting that the mutation detected in the patient leads to hemizygous loss of function, which is the known disease mechanism for the gene. However, the score was not upgraded since the analysis was performed using muscle biopsy samples. But this evidence supported that the variant results in loss-of-function. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 45-55 was observed in a single male in gnomAD. However, no deletion containing exclusively exon 45 has been observed in gnomAD. Since different deletions with distinct exon content can lead to different effects in the transcript, the variant was slightly downgraded (-0.25).
High confidence in phenotypic quality. ",0-2,1.0,0.75
131,"Wu JY, et al. (2006): Association of Duchenne muscular dystrophy with autism spectrum disorder",16417872.0,Patient 8,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: Diagnosis of autism spectrum disorder/pervasive developmental disorder was determined by a pediatric neurologist in agreement with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Criteria,,c.278A>G,p.H93R,"Default score downgraded for genotypic evidence.
CNV loss of unknown inheritance identified by polymerase chain reaction analysis (PCR). Due to the targeted approach and limited resolution of the genotyping methods, the score was downgraded (-0.5). Through muscle biopsy analysis, it was determined that the patient has no dystrophin expression, supporting that the mutation detected in the patient leads to hemizygous loss of function, which is the known disease mechanism for the gene. However, the score was not upgraded since the analysis was performed using muscle biopsy samples. But this evidence supported that the variant results in loss-of-function. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 45-55 was observed in a single male in gnomAD. Although CNV deletions with different exon content result in distinct effects in the transcript, due to the considerable overlap between the CNV loss in gnomAD and the patient's CNV, the score was downgraded (-0.5)
High confidence in phenotypic quality. ",0-2,1.0,0.5
132,"Wu JY, et al. (2006): Association of Duchenne muscular dystrophy with autism spectrum disorder",16417872.0,Patient 9,DMD,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: Diagnosis of autism spectrum disorder/pervasive developmental disorder was determined by a pediatric neurologist in agreement with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Criteria,,c.755A>G,p.D252G,"Default score downgraded for genotypic evidence.
CNV loss of unknown inheritance identified by polymerase chain reaction analysis (PCR). Due to the targeted approach and limited resolution of the genotyping methods, the score was downgraded (-0.5). Through muscle biopsy analysis, it was determined that the patient has no dystrophin expression, supporting that the mutation detected in the patient leads to hemizygous loss of function, which is the known disease mechanism for the gene. However, the score was not upgraded since the analysis was performed using muscle biopsy samples. But this evidence supported that the variant results in loss-of-function. The exact breakpoints of the deletion were not defined by the molecular test, challenging the comparison with variants reported in gnomAD. A larger deletion containing exon 3-9 was observed in 2 hemizygous males in gnomAD. Although CNV deletions with different exon content result in distinct effects in the transcript, due to the considerable overlap between the CNV loss in gnomAD and the patient's CNV, the score was downgraded (-0.5)
High confidence in phenotypic quality. ",0-2,1.0,0.5
141,Qin Y et al. (2022): A recurrent SHANK1 mutation implicated in autism spectrum disorder causes autistic-like core behaviors in mice via downregulation of mGluR1-IP3R1-calcium signaling,35388181.0,ASD170P,SHANK1,: Maternally Inherited (No psychiatric disorders were determined in the mother),Other variant type not predicted/proven null (not de novo),High Confidence in Phenotype,"ASD: ASD participants were enrolled from the Department of Child and Adolescent Psychiatry from the Shanghai Mental Health Center. ASD patients were diagnosed with ASD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) of the American Psychiatric Association (APA). The parents of the patients with ASD were evaluated with the Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS)",g.51160432GA>G,c.4172delA,p.Glu1391Asp,"Default score applied after modification for genotypic evidence and functional evidence. 
Maternally inherited missense variant identified by mutational screening of the coding sequences and adjacent splice sites of SHANK1 and validated by bi-directional sequencing. The variant affects a moderately conserved residue located in a region with no functional domain. However, the variant has been reported in gnomAD and ClinVar classified the variant as VUS. Since the SHANK1 was the only genotyped gene in the study and the variant was detected in gnomAD, the score was downgraded. However, the default score was applied on the basis of functional evidence that supports the pathogenicity of this missense substitution. In vitro and in vivo evidence showed that the missense variant affects the function of the SHANK1 protein. In vitro analysis of mice hippocampal neurons showed that this missense variant affect the morphology of dendritic spines, resulting in reduced size. Furthermore, a knockin mouse model showed that mutant mice carrying this variant displayed core ASD symptoms such as deficits in social novelty preference and presence of repetitive behaviors. Although functional evidence supports the pathogenicity of the variant, the missense substitution was interpreted as other variant type, not predicted/proven null.
High confidence in phenotypic quality. ",0-0.1,0.0,0.1
142,Qin Y et al. (2022): A recurrent SHANK1 mutation implicated in autism spectrum disorder causes autistic-like core behaviors in mice via downregulation of mGluR1-IP3R1-calcium signaling,35388181.0,ASD184P,SHANK1,: Maternally Inherited (The mother was diagnosed with moderate depression and mild anxiety) | Variant reported: hg(38) g. 50672071 C > T; NM_016148.4: c.2621 G > A; (p.R874H) Impact: Missense variant (The variant affects a highly conserved residue located outside of the functional domains of the protein) gnomAD: 55/1613944 = 0.00003408. A different missense variant at this position is classified on ClinVar as VUS (p.R874L; ID: 2462138) Inheritance: Maternally Inherited (The mother was diagnosed with moderate depression and mild anxiety),Other variant type not predicted/proven null (not de novo),High Confidence in Phenotype,"ASD: ASD participants were enrolled from the Department of Child and Adolescent Psychiatry from the Shanghai Mental Health Center. ASD patients were diagnosed with ASD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) of the American Psychiatric Association (APA). The parents of the patients with ASD were evaluated with the Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS)",g.51117766T>G,c.T795G,p.H265Q,"Default score applied after modification for genotypic evidence and functional evidence. 
Two maternally inherited missense variants identified by mutational screening of the coding sequences and adjacent splice sites of SHANK1 and validated by bi-directional sequencing. Since both missense variants were inherited from the mother, they are located in cis in the same chromosome. For that reason, only the second missense substitution (p.R874H), which shows the most compelling pathogenicity evidence, was scored. This missense variant affects a highly conserved residue located outside of the functional domains of the protein. Since the SHANK1 was the only genotyped gene in the study and the variant was detected in gnomAD, the score was downgraded. However, the default score was applied on the basis of functional evidence supporting the pathogenicity of this non-synonymous variant. In vitro and in vivo experiments showed that the pR874H variant is detrimental to SHANK1 function and induces ASD-like phenotypes in mice. In vitro analysis showed that expression of the missense variant in rat hippocampal neurons results in decreased size of dendritic spine length and width. Furthermore, a knockin mouse model showed that mutant mice carrying this variant displayed core ASD symptoms such as deficits in social novelty preference and presence of repetitive behaviors. Finally, mutant mice showed dysregulaltion of the mGluR1-IP3R1-calcium signaling pathway in specific brain regions, which may contribute to the ASD phenotypes observed. Although functional evidence supports the pathogenicity of the variant, the missense substitution was interpreted as other variant type, not predicted/proven null.
High confidence in phenotypic quality. ",0-0.1,0.0,0.1
143,Qin Y et al. (2022): A recurrent SHANK1 mutation implicated in autism spectrum disorder causes autistic-like core behaviors in mice via downregulation of mGluR1-IP3R1-calcium signaling,35388181.0,ASD200P,SHANK1,: Paternally Inherited (The father was diagnosed with mild depression and mild anxiety) | Variant reported: hg(38) g. 50662341 C > T; NM_016148.4: c.6110 G > A; (p.G2037D) Impact: Missense variant (The variant affects a moderately conserved residue located outside of the functional domains of the protein) gnomAD: NA Inheritance: Maternally Inherited (No psychiatric disorder was observed in the mother),Other variant type not predicted/proven null (not de novo),High Confidence in Phenotype,"ASD: ASD participants were enrolled from the Department of Child and Adolescent Psychiatry from the Shanghai Mental Health Center. ASD patients were diagnosed with ASD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) of the American Psychiatric Association (APA). The parents of the patients with ASD were evaluated with the Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS)",g.51143237G>A,c.G1801A,p.V631M,"Default score applied after modification for genotypic and functional evidence. 
Compound heterozygous missense variants  identified by mutational screening of the coding sequences and adjacent splice sites of SHANK1 and validated by bi-directional sequencing. Since these variants were independently inherited from each parent, each variant was evaluated separately. First, the paternally inherited missense variant has been observed in gnomAD and affects a poorly conserved residue located outside of the functional domains. Although in vitro experiments showed that the missense variant affects the morphology of dendritic spines, the score was downgraded to 0 since the variant is observed in gnomAD and the residue is not evolutionarily conserved.
On the other hand, the maternally inherited missense variant is absent in gnomAD and affects a moderately conserved residue located outside of the functional domains of the protein. Similalry, in vitro experiments showed that the missense variant reduces the length and width of dendritic spines. Based on this evidence, the default score was applied. 
High confidence in phenotypic quality. ",0-0.1,0.0,0.1
144,Qin Y et al. (2022): A recurrent SHANK1 mutation implicated in autism spectrum disorder causes autistic-like core behaviors in mice via downregulation of mGluR1-IP3R1-calcium signaling,35388181.0,ASD488P,SHANK1,: de novo,Variant is de novomissense,High Confidence in Phenotype,"ASD: ASD participants were enrolled from the Department of Child and Adolescent Psychiatry from the Shanghai Mental Health Center. ASD patients were diagnosed with ASD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) of the American Psychiatric Association (APA). The parents of the patients with ASD were evaluated with the Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS)",,c.3679dupG,p.Ala1227fs,"Default score applied after modification for genotypic evidence and functional evidence. 
De novo missense variant identified by mutational screening of the coding sequences and adjacent splice sites of SHANK1 and validated by bi-directional sequencing. The score was downgraded since SHANK1 was the only gene investigated (-0.25). The variant affects a moderately conserved residue located in a region with no functional domain. However, the variant has been reported in gnomAD and ClinVar classified the variant as VUS (-0.25). However, the score was upgraded on the basis of functional evidence that supports the pathogenicity of this missense substitution (+0.5). In vitro and in vivo evidence showed that the missense variant affects the function of the SHANK1 protein. In vitro analysis of mice hippocampal neurons showed that this missense variant affect the morphology of dendritic spines, resulting in reduced size. Furthermore, a knockin mouse model showed that mutant mice carrying this variant displayed core ASD symptoms such as deficits in social novelty preference and presence of repetitive behaviors.
High confidence in phenotypic quality. ",0-1,0.0,0.5
145,Qin Y et al. (2022): A recurrent SHANK1 mutation implicated in autism spectrum disorder causes autistic-like core behaviors in mice via downregulation of mGluR1-IP3R1-calcium signaling,35388181.0,ASD837P,SHANK1,: De novo,Variant is de novomissense,High Confidence in Phenotype,"ASD: ASD participants were enrolled from the Department of Child and Adolescent Psychiatry from the Shanghai Mental Health Center. ASD patients were diagnosed with ASD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) of the American Psychiatric Association (APA). The parents of the patients with ASD were evaluated with the Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS)",,c.3679dupG,p.Ala1227fs,"Default score applied after modification for genotypic evidence and functional evidence. 
De novo missense variant identified by mutational screening of the coding sequences and adjacent splice sites of SHANK1 and validated by bi-directional sequencing. The score was downgraded since SHANK1 was the only gene investigated (-0.25). This missense variant affects a highly conserved residue located outside of the functional domains of the protein. The variant has been reported in gnomAD (-0.25). However, the score was upgraded on the basis of functional evidence that supports the pathogenicity of this missense substitution (+0.5). In vitro and in vivo experiments showed that the pR874H variant is detrimental to SHANK1 function and induces ASD-like phenotypes in mice. In vitro analysis showed that expression of the missense variant in rat hippocampal neurons results in decreased size of dendritic spine length and width. Furthermore, a knockin mouse model showed that mutant mice carrying this variant displayed core ASD symptoms such as deficits in social novelty preference and presence of repetitive behaviors. Finally, mutant mice showed dysregulation of the mGluR1-IP3R1-calcium signaling pathway in specific brain regions, which may contribute to the ASD phenotypes observed.
High confidence in phenotypic quality. ",0-1,0.0,0.5
152,Paprocka J et al. (2021): Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant,34912368.0,Single case report,SHANK1,: de novo (mosaic variant detected in 21% of all reads. Co-segregation analysis confirmed the variant is de novo and showed mosaicism at the level of 19% reads),Mosaic ,Low Confidence in Phenotype,"ASD: The clinical description of the case includes autistic behavior. However, the case was not diagnosed with ASD by the implementation of standardized criteria. A detailed description of the autistic features was not provided",,,,"Default score downgraded for phenotypic evidence. 
Mosaic missense variant identified through trio-based whole exome sequencing at an alternative allele frequency of 0.21. Co-segregation analysis confirmed that the variant is mosaic and absent in the parents. Therefore, the variant was assessed as de novo missense with default score of 0.5. The non-synonymous variant affects a highly conserved residue located within a previously unknown functional domain, which might mediate protein-protein interactions. The missense substitution is absent in gnomAD, but a different amino-acid change is reported. Through in silico prediction tools and protein modeling it was determined that the variant is likely damaging to protein function by disrupting the interaction with Rap1. However, functional experiments were not performed to confirmed these predictions, thus the score was not upgraded. 
On the other hand, the score was donwgraded for low confidence in phenotypic quality (-0.25).",,0.0,0.25
153,May HJ et al. (2021): Truncating variants in the SHANK1 gene are associated with a spectrum of neurodevelopmental disorders,34113010.0,Patient 2,SHANK1,: de novo,Variant is de novo,High Confidence in Phenotype,"ASD: The case was ascertained via contact with the primary clinician with the use of GeneMatcher. Diagnosis of Autism spectrum disorder was determined by a developmental pediatrician at the age of 3 years, based on the presence of symptoms consistent with ASD, including poor social interaction, repetitive behaviors and restricted interests",g.51137146G>A,c.1527G>A,p.Trp509*,"Default score upgraded for functional evidence.
De novo nonsense mutation identified through trio-based exome sequencing and validated by Sanger sequencing. The variant creates a premature stop codon in the penultimate exon of the gene. Functional experiments supports the pathogenicity of the variant, thus the score was upgraded (+0.5). Functional analysis showed that mutant transcripts escaped the nonsense mediated mRNA pathway. However, the mutant protein lacks important protein domains that mediates protein-protein interactions with post-synaptic proteins. In particular, the mutant protein lost its ability to bind to Homer1, an important protein partner in the post-synpatic density. As a consequence, the mutated protein displayed an abnormal localization in the post-synaptic region, which can results in reduced synaptic maturation. The nonsense mutation is absent in gnomAD. 
High confidence in phenotypic quality. ",0-2.5,2.0,2.5
154,May HJ et al. (2021): Truncating variants in the SHANK1 gene are associated with a spectrum of neurodevelopmental disorders,34113010.0,Patient 4,SHANK1,: de novo,Variant is de novo,High Confidence in Phenotype,ASD: The case was ascertained via contact with the primary clinician with the use of GeneMatcher. Diagnosis of ASD was determined with the ADOS-2 at the age of 10 years,g.51158732delC,c.2471delC,p.Pro824Arg,"Default score downgraded for genotypic evidence.
De novo nonsene mutation identified through trio-based exome sequencing and validated by Sanger sequencing. The variant creates a premature stop codon in exon 10 out of 24. Therefore, the variant results in loss of function due to the nonsense mediated mRNA pathway or the synthesis of a truncated protein that lacks functional domains, in a gene for which loss of function is the most likely disease mechanism. However, the variant is reported in gnomAD at an extremely low allele frequency (-0.5). 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
155,May HJ et al. (2021): Truncating variants in the SHANK1 gene are associated with a spectrum of neurodevelopmental disorders,34113010.0,Patient 5,SHANK1,: de novo,Variant is de novo,Medium Confidence in Phenotype,"ASD: The case was ascertained by searching the Database of Chromosomal Imbalances and Phenotype in Humans Using Ensembl Resources. The case was diagnosed with autism at the age of 2 years and 9 months of age. However, the criteria used to determine the diagnosis of ASD was not documented in the study. On the other hand, his clinical symptoms are consistent with the hallmarks of ASD, including repetitive behaviors, lack of interest for the surroundings and poor language development",g.51159207_51159210delCCGC,c.2946_2949delCCGC,p.Arg983Ser,"Default score downgraded for phenotypic evidence.
De novo frameshift mutation identified through trio-based exome sequencing and validated by Sanger sequencing. The frameshift variant creates a premature stop codon in the penultimate exon of the gene. Upstream premature stop codon-inducing variants have been shown to escape the nonsense mediated mRNA pathway. However, the truncated protein is predicted to lack the C-terminal SAM domain. Therefore, the mutation is likely to result in loss of function, which represents the most likely disease mechanism for SHANK1. But no functional evidence is available to support its pathogenicity, thus no score upgrades were applied. The frameshift variant is absent in gnomAD. 
However, the score was downgraded for medium confidence in phenotypic quality (-0.5). Although the methods employed to determine the diagnosis of ASD were not documented, the patient's symptoms are consistent with the core phenotype of ASD. ",0-2.5,2.0,1.5
156,"Wang T, et al. (2016): De novo genic mutations among a Chinese autism spectrum disorder cohort",27824329.0,SKLMG_M23139,SHANK1,: De novo,Variant is de novo canonical splice site,High Confidence in Phenotype ,ASD: The proband is part of the Autism Clinical and Genetics Resources in China (ACGC). All diagnosis were ascertained according to the DSM-IV criteria. Families were excluded if proband did not meet the diagnostic criteria,g.51160024C>G,c.C3721G,p.R1241G,"Default score downgraded for genotypic evidence.
De novo canonical donor splice variant identified through targeted sequencing of a panel of 189 ASD candidate risk genes using single molecule molecular inversion probes. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD. The variant is located within the canonical donor site in intron 20, thus likely resulting in aberrant mRNA splicing.  However, no function evidence is available for this variant.
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
157,"Sato D, et al. (2012): SHANK1 Deletions in Males with Autism Spectrum Disorder",22503632.0,Proband; Family 1 Individual III-5,SHANK1,": Maternally Inherited (The mother, individual II-4, has exhibited anxiety and shyness for most of her life but would not be considered to have ASD or Broad Autism Phenotype (BAP). Even though both parents were assessed with an extensive battery of tools, both of them scored in the typical range)",Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: The study assessed microarray data from a cohort of 1158 unrelated Canadian individuals and 456 European individuals with a clinical diagnosis of ASD. All ASD patients were evaluated by expert clinicians on the basis of the Autism Diagnostic Interview-Revised (ADI-R) and/or the Autism Diagnostic Observation Schedule (ADOS). For some European cases, the Diagnostic Interview for Social and Communication Disorder (DISCO-10) was applied instead of the ADI-R. Moreover, the Social Responsiveness Scale (SRS) was also administered",g.51153464G>A,,p.A752T,"Default score applied. 
Maternally inherited CNV deletion identified through high-resolution microarray analysis and validated by orthogonal methods. The CNV loss contains exons 1-20 of SHANK1 and the entire coding sequence of CLEC11A. No CNV deletions with 50% overlap in SHANK1 are reported in gnomAD, while deletions overlapping the entire coding sequence of CELC11A are observed in gnomAD. Although the CNV loss was detected by microarray analysis, additional whole exome sequencing allowed to identified only a nonsense variant in the gene PCDHGA11. This genes has not been associated with ASD risk nor with any disease phenotype. Furthermore, the gene is not intolerant to loss of function variation. Although PCDHGA11 encodes a neural cadherin-like cell adhesion protein involved in cell-cell connections in the brain, there is no robust evidence that supports that loss of function mutations in this gene contribute to the ASD phenotype. On the other hand, the CNV deletion containing SHANK1 co-segregates with the phenotype across multiple generations in this pedigree. In particular, heterozygous males are diagnosed with high-functioning autism, while female carries present a different phenotype characterized by anxiety and shyness but they did not meet the criteria for ASD. Based on all the genotypic evidence, the default score was applied.
High confidence in phenotypic quality. ",0-2,1.0,1.5
169,Du X et al. (2021): Genetic Testing in Patients with Neurodevelopmental Disorders: Experience of 511 Patients at Cincinnati Children's Hospital Medical Center,34773222.0,Patient 18,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype ,"ASD: The study included cases with diagnosis of different neurodevelopmental disorder who underwent molecular diagnosis at Cincinnati Children's Hospital Medical Center (CCHMC). The case was diagnosed with Autism spectrum disorder, but the criteria and methods used to evaluate the phenotype of the patient was not provided in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Missense mutation of unknown inheritance identified by targeted sequencing of the coding regions of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5).  The missense variant is absent in gnomAD, but reputable databases such a ClinVar and OMIM reports the variant as pathogenic. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein abolishing the ability of the protein to bind DNA. For these reasons, the variant was interpreted as predicted/proven null. However, the score was not further upgraded since it is a recurrent variant among affected cases with Rett syndrome. This was done to prevent overestimating the score. 
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
170,Chen JS et al. (2021): Comorbidities associated with genetic abnormalities in children with intellectual disability,33753861.0,Patient 47,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: The cases included in the study were recruited on the basis of diagnosis of ID as the primary diagnostic criteria. When autistic traits or ADHD was suspected during the assessment by the psychologist, further tests were performed. Diagnosis of ASD was further confirmed by certified pediatric psychiatrist based on the DSM-V criteria",,,,"Default score applied. 
Nonsense mutation of unknown inheritance identified through whole exome sequencing and validated by Sanger sequencing. The variant is absent in gnomAD. 
High confidence in phenotypic quality. ",0-2,1.0,1.5
171,"Inuzuka LM, et al. (2021): MECP2-related conditions in males: A systematic literature review and 8 additional cases.",34271245.0,Patient 7,MECP2,: de novo,Variant is de novomissense,Low Confidence in Phenot,ASD: Conventional diagnosis of ASD was not determined for this case but the case description includes autistic behavior. The methods used to assess the phenotype were not described in the study,,,,"Default score downgraded for phenotypic evidence.
De novo missense variant detected by Whole exome sequencing and validated by Sanger sequencing. The non-synonymous change is absent in gnomAD, but no functional evidence is available for this variant. This substitution has not been observed in previous cases with Rett syndrome. 
However, the score was downgraded due to low confidence in phenotypic quality (-0.25). ",0-1,0.0,0.25
173,Amadori E et al. (2020): Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project,32631363.0,Patient 2,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype ,"ASD: The cases included in the study received a diagnosis of epilepsy as the primary diagnostic criteria. Subjects were between 24-60 months, with the first unprovoked seizure occurring after the second year of life. Patient data was obtained from clinical records and collected through a questionnaire provided by the referring clinicians. Autistic-like behavior was included in the phenotypic description of the case (Table 1). However, the methods used to assess the autistic behavior were not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence.
Frameshift deletion of unknown inheritance identified by next generation targeted sequencing of a panel of 283 genes and validated by Sanger sequencing. Due to the limited number of genes included in the analysis, the score was downgraded (-0.5). The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25).
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.25
174,Amadori E et al. (2020): Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project,32631363.0,Patient 12,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype ,"ASD: The cases included in the study received a diagnosis of epilepsy as the primary diagnostic criteria. Subjects were between 24-60 months, with the first unprovoked seizure occurring after the second year of life. Patient data was obtained from clinical records and collected through a questionnaire provided by the referring clinicians. Autistic-like behavior was included in the phenotypic description of the case (Table 1). However, the methods used to assess the autistic behavior were not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Missense mutation of unknown inheritance identified through next generation targeted sequencing of a panel of 283 genes associated with epilepsy. The variant was furher validated by Sanger sequencing. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. For these reasons, the variant was scored as predicted/proven null. However, the score was not further upgraded since it is a recurrent disease-causing mutation among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
175,Amadori E et al. (2020): Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project,32631363.0,Patient 13,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype ,"ASD: The cases included in the study received a diagnosis of epilepsy as the primary diagnostic criteria. Subjects were between 24-60 months, with the first unprovoked seizure occurring after the second year of life. Patient data was obtained from clinical records and collected through a questionnaire provided by the referring clinicians. Autistic-like behavior was included in the phenotypic description of the case (Table 1). However, the methods used to assess the autistic behavior were not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Nonsense mutation of unknown inheritance identified through next generation sequencing of a panel of 283 Epilepsy associated genes. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The variant is absent in gnomAD, but reputable databases interpreted the variant as pathogenic. Experimental data, from well-established in vitro and in vivo studies showed that the variant impairs the function of the protein, affecting the transcirption repressor activity and binding to interacting partners. However, the score was not upgraded since it is a recurrent mutation among affected individuals. This decision was made to prevent an overestimation of the score. 
The score was further downgraded for low confidence of phenotypic quality (-0.5). ",0-2,1.0,0.5
177,"Gu Y, et al. (2020): Three intellectual disability-associated de novo mutations in MECP2 identified by trio-WES analysis.",32393352.0,Case 2,MECP2,: de novo,Variant is de novomissense,Medium Confidence in Phenotype,"ASD: The primary inclusion criteria was diagnosis of ID and possible accompanying conditions. Diagnosis of ASD was possible after evaluation with the Clancy Autism Behavior Scale. However, other gold-standard tools such as ADOS could not be carried out due to lack of compliance. On the other hand, the patients symptoms are consistent with the main features of ASD including lack of social interest and presence of stereotypic behaviors",,,,"Default score downgraded for phenotypic evidence.
De novo missense mutation identified through trio-based whole exome sequencing and validated by Sanger sequencing. The non-synonymous substitution is absent in gnomAD, but it is reported as a pathogenic mutation by reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the missense mutation has been demonstrated by well-established in vitro and in vivo mouse models. Trangenic mice carrying this variant develop Rett-like phenotypes; and at the molecular level, the mutation affects the interaction of MeCP2 with transcriptional co-repressor complexes. Although functional evidence is available, the score was not upgraded since this mutation is recurrent in cases with Rett syndrome. This decision was made to avoid overstimating the score. 
The score was downgraded for medium confidence in phenotypic quality (-0.1). ",0-1,0.0,0.4
178,Hettiarachchi D (2020): Variant Profile of MECP2 Gene in Sri Lankan Patients with Rett Syndrome,31535341.0,Proband 2,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The cases included in this study were referred to the Human Genetics Unit, Faculty of Medicine, University of Colombo. Patients were screened by a Neurologist using revised diagnostic criteria and nomenclature. Inclusion criteria required the presence of regression, loss of acquired purposeful hand skills and spoken language, gait abnormalities and stereotypic hand movements. After referral from the neurologist, the patients were re-evaluated by a clinical geneticist before molecular testing. The present case has features of autism with associated learning disabilities. But official diagnosis of ASD was not established for the case",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Nonsense mutation of unknown inheritance identified through targeted sequencing of MeCP2. Since it was the only gene analyzed, the score was downgraded (-0.5). The variant is absent in gnomAD, but reputable databases interpreted the variant as pathogenic. Experimental data, from well-established in vitro and in vivo studies showed that the variant impairs the function of the protein, affecting the transcirption repressor activity and binding to interacting partners. However, the score was not upgraded since it is a recurrent mutation among affected individuals. This decision was made to prevent an overestimation of the score. 
The score was further downgraded due to  low confidence of phenotypic quality (-0.5). ",0-2,1.0,0.5
179,Hettiarachchi D (2020): Variant Profile of MECP2 Gene in Sri Lankan Patients with Rett Syndrome,31535341.0,Proband 5,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The cases included in this study were referred to the Human Genetics Unit, Faculty of Medicine, University of Colombo. Patients were screened by a Neurologist using revised diagnostic criteria and nomenclature. Inclusion criteria required the presence of regression, loss of acquired purposeful hand skills and spoken language, gait abnormalities and stereotypic hand movements. After referral from the neurologist, the patients were re-evaluated by a clinical geneticist before molecular testing. The present case has features of autism with associated learning disabilities. But official diagnosis of ASD was not established for the case",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Missense mutation of unknown inheritance identified by targeted sequencing of the coding regions of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5).  The missense variant is absent in gnomAD, but reputable databases such a ClinVar and OMIM reports the variant as pathogenic. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein abolishing the ability of the protein to bind DNA. For these reasons, the variant was interpreted as predicted/proven null. However, the score was not further upgraded since it is a recurrent variant among affected cases with Rett syndrome. This was done to prevent overestimating the score. 
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
180,Hettiarachchi D (2020): Variant Profile of MECP2 Gene in Sri Lankan Patients with Rett Syndrome,31535341.0,Proband 7,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The cases included in this study were referred to the Human Genetics Unit, Faculty of Medicine, University of Colombo. Patients were screened by a Neurologist using revised diagnostic criteria and nomenclature. Inclusion criteria required the presence of regression, loss of acquired purposeful hand skills and spoken language, gait abnormalities and stereotypic hand movements. After referral from the neurologist, the patients were re-evaluated by a clinical geneticist before molecular testing. The present case has features of autism with associated learning disabilities. But official diagnosis of ASD was not established for the case",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Missense mutation of unknown inheritance identified by targeted sequencing of the coding regions of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5).  The missense variant is absent in gnomAD, but reputable databases such a ClinVar and OMIM reports the variant as pathogenic. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein abolishing the ability of the protein to bind DNA. For these reasons, the variant was interpreted as predicted/proven null. However, the score was not further upgraded since it is a recurrent variant among affected cases with Rett syndrome. This was done to prevent overestimating the score. 
The score was further downgraded for low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
184,"Long S, et al. (2019): The Clinical and Genetic Features of Co-occurring Epilepsy and Autism Spectrum Disorder in Chinese Children",31139143.0,P023,MECP2,de novo,Variant is de novomissense,High Confidence in Phenotype ,"ASD: The study retrospectively recruited patients with a comorbid diagnosis of ASD and epilepsy from the National Children's Medical Center, Shanghai, China. Primary data were collected from electronic clinical history systems and medical records using key words ""Autism/ASD and epilepsy/seizure"". ASD was first assessed using the Autism Behavior Checklist, completed by parents, and probands with at least 18-months old. When the score was >61, ASD was considered. Then, all ASD candidate patients were diagnosed by qualified and experienced neurologists and psychologists using the Diagnostic and Statistical Manual of Mental Disorder V (DSM-V). Diagnosis was based on evidence available from the ADOS and the ADI-R. ASD severity was assessed using the DSM-V criteria and categorized into mild, moderate or severe. Patients with ASD-like features but failed to met the diagnostic criteria were excluded",,,,"Default score applied.
De novo missense mutation identified through whole exome sequencing and validated by Sanger sequencing for segregation analysis. The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. However, the score was not upgraded since it is a recurrent variant among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
185,"Long S, et al. (2019): The Clinical and Genetic Features of Co-occurring Epilepsy and Autism Spectrum Disorder in Chinese Children",31139143.0,P027,MECP2,de novo,Variant is de novomissense,High Confidence in Phenotype ,"ASD: The study retrospectively recruited patients with a comorbid diagnosis of ASD and epilepsy from the National Children's Medical Center, Shanghai, China. Primary data were collected from electronic clinical history systems and medical records using key words ""Autism/ASD and epilepsy/seizure"". ASD was first assessed using the Autism Behavior Checklist, completed by parents, and probands with at least 18-months old. When the score was >61, ASD was considered. Then, all ASD candidate patients were diagnosed by qualified and experienced neurologists and psychologists using the Diagnostic and Statistical Manual of Mental Disorder V (DSM-V). Diagnosis was based on evidence available from the ADOS and the ADI-R. ASD severity was assessed using the DSM-V criteria and categorized into mild, moderate or severe. Patients with ASD-like features but failed to met the diagnostic criteria were excluded",,,,"Default score applied.
De novo missense mutation identified through whole exome sequencing and validated by Sanger sequencing for segregation analysis. The non-synonymous substitution is absent in gnomAD, but it is reported as a pathogenic mutation by reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the missense mutation has been demonstrated by well-established in vitro and in vivo mouse models. Trangenic mice carrying this variant develop Rett-like phenotypes; and at the molecular level, the mutation affects the interaction of MeCP2 with transcriptional co-repressor complexes. Although functional evidence is available, the score was not upgraded since this mutation is recurrent in cases with Rett syndrome. This decision was made to avoid overstimating the score. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
186,"Long S, et al. (2019): The Clinical and Genetic Features of Co-occurring Epilepsy and Autism Spectrum Disorder in Chinese Children",31139143.0,P046,MECP2,de novo,Variant is de novomissense,High Confidence in Phenotype ,"ASD: The study retrospectively recruited patients with a comorbid diagnosis of ASD and epilepsy from the National Children's Medical Center, Shanghai, China. Primary data were collected from electronic clinical history systems and medical records using key words ""Autism/ASD and epilepsy/seizure"". ASD was first assessed using the Autism Behavior Checklist, completed by parents, and probands with at least 18-months old. When the score was >61, ASD was considered. Then, all ASD candidate patients were diagnosed by qualified and experienced neurologists and psychologists using the Diagnostic and Statistical Manual of Mental Disorder V (DSM-V). Diagnosis was based on evidence available from the ADOS and the ADI-R. ASD severity was assessed using the DSM-V criteria and categorized into mild, moderate or severe. Patients with ASD-like features but failed to met the diagnostic criteria were excluded",,,,"Default score applied.
De novo missense mutation identified through whole exome sequencing and validated by Sanger sequencing. The missense variant is absent in gnomAD, but reputable databases such a ClinVar and OMIM reports the variant as pathogenic. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein abolishing the ability of the protein to bind DNA. However, the score was not upgraded since it is a recurrent variant among affected cases with Rett syndrome. This was done to prevent overestimating the score. 
High confidence in phenotypic quality. ",0-1,0.0,0.5
187,"Balicza P, et al. (2019): Comprehensive Analysis of Rare Variants of 101 Autism-Linked Genes in a Hungarian Cohort of Autism Spectrum Disorder Patients",31134136.0,P8,MECP2,: de novo,Variant is de novo,High Confidence in Phenotype ,"ASD: The patients included in the study were recruited from the Vadaskert Child and Adolescent Psychiatry Hospital and Outpatient Clinic. Detailed clinical evaluation were performed by neurologist. Diagnosis of ASD was determined by a qualified psychologist using the AD-R and ADOS. Family history, detailed environemental/social data were collected from the parents of each patient. Diagnosis of ASD was based on the standardized AD-R in Hugarian, which was published by the Autism Foundation",,,,"Default score downgraded for genotypic evidence. 
De novo nonsense mutation identified through targeted sequencing of a panel of 101 ASD-associated genes. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The variant is absent in gnomAD but it is reported as a well-known pathogenic mutation in reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the varinant has been proven by well-established in vitro studies, showing that the variant impairs the non-methylated DNA binding affinity and the transcriptional repression activity. However, the score was not upgraded since this variant is a recurrent mutation in cases with Rett syndrome. This decision was made to avoid overestimating the score. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
190,"Guo H, et al. (2018): Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model",30564305.0,M31872,MECP2,: de novo,Variant is de novo,High Confidence in Phenotype ,ASD: The proband is part of the Autism Clinical and Genetics Resources in China (ACGC). Clinical diagnosis was ascertained according to the DSM-IV criteria. Additional tools used to evaluate autisitic features included the Social Responsiveness Scale (SRS),,,,"Default score downgraded for genotypic evidence. 
De novo nonsense mutation identified through targeted sequencing of a panel of 187 ASD-risk genes using single molecule molecular inversion probes and validated by Sanger sequencing. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The variant is absent in gnomAD but it is reported as a well-known pathogenic mutation in reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the varinant has been proven by well-established in vitro studies, showing that the variant impairs the non-methylated DNA binding affinity and the transcriptional repression activity. However, the score was not upgraded since this variant is a recurrent mutation in cases with Rett syndrome. This decision was made to avoid overestimating the score. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
195,"Ghorbel R, et al. (2018): First report of an unusual novel double mutation affecting the transcription repression domain of MeCP2 and causing a severe phenotype of Rett syndrome: Molecular analyses and computational investigation",29421650.0,Single case report,MECP2,: de novo,Variant is de novo,Low Confidence in Phenotype,"ASD: No official diagnosis of ASD was determine for this case. However, the clinical description of the case includes autistic behavior including the presence of stereotypic hand movements",,,,"Default score downgraded for genotypic and phenotypic evidence.
This is the first case with a double mutation detected in MeCP2, a nonsense and missense variant. Although the present case developed a more severe clinical phenotype, compared to other cases, who are carriers of the p.R294*, the phasing of the variants was not determined. Therefore, it is unknown if the variants are in trans. For that reason, the case was scored based on the variant with the more severe impact (i.e. nonsense mutation). The nonsense variant was detected by direct sequencing of the exons and exon-intron boundaries of the MeCP2 gene. The score was downgraded due to the targeted sequencing approach and lack of genome-wide analysis (-0.5) The variant was absent in the parents and healthy sister (i.e de novo) and it is absent in gnomAD. The pathogenicity of the variant has been confirmed by in vivo and in vitro functional experiments showing that the nonsense mutation impairs the function of the protein, in particular, the transcriptional repression activity and protein stability. Although functional evidence is available that support its pathogenicity, the score was not upgraded, since it is a common variant observed in several cases. This decision was made to prevent overestimating the score.
The score was further downgraded for low confidence in phenotypic quality (-1). ",0-2.5,2.0,0.5
196,"Li J, et al. (2017): Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in autism spectrum disorders",28831199.0,Patient: 19717,MECP2,: de novo,Variant is de novo,High Confidence in Phenotype,"ASD: The ASD cases included in the study were recruited from the Autism Clinical and Genetic Resources in China (ACGC). This is a well-characterized ASD cohort, all diagnosis were ascertained according to the DSM-IV criteria. Families were excluded if proband did not meet the diagnostic criteria",,,,"Default score downgraded for genotypic evidence. 
De novo nonsense mutation identified through targeted sequencing of a panel of 194 genes and validated by Sanger sequencing. Given limited number of genes, the score was downgraded (-0.5). The variant is absent in gnomAD but reputable resources report the variant as a well-known pathogenic mutation. The pathogenicity of the variant has been demonstrated by well-established in vivo and in vitro experiments. Transgenic mice models, harbouring this variant, develop severe features, resembling Rett-like phenotypes. At the molecular level, the variant impairs the transcriptional repressor activity of the protein. Regardless of the functional evidence, the score was not upgraded since, it is a recurrent mutation among Rett syndrome patients. This decision was made to prevent overestimating the score. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
197,"Wen Z, et al. (2017):  Identification of autism-related MECP2 mutations by whole-exome sequencing and functional validation",28785396.0,Patient 138,MECP2,: de novo,Variant is de novomissense,High Confidence in Phenotype,"ASD: Diagnosis of ASD was determined according to the DSM-IV criteria. Cases suffering with severe somatic disorder such as cardiomyopathy and epilepsy were excluded from the study. On the other hand, diagnosis of Rett syndrome was excluded in this case. Collected a comprehensive profile including detailed developmental history, family background. All the clinical information is classified accordance with the diagnostic items of ASD in DSM-IV: social interaction, language, repetitive behaviors and functional impairments. Other assessments instruments included the Child Autism Rating Scale Score (CARS) and Autism behavior checklist (ABC)",,,,"Default score upgraded for functional evidence.
De novo missense variant identified through whole exome sequencing and validated by Sanger sequencing. This missense variant is absent in gnomAD, but different amino-acids changes are reported at this position. One of them interpreted as likely pathogenic. The study carried out functional experiments to determine the effect of this variant. The mutated protein affected the development of neurons, lacking the ability to inhibit dendrite formation. Based on this evidence, the score was partially upgraded (+0.25) since it is not known how the variant affects protein function. No other cases with autism/autistic features are reported with this variant, thus the score upgrade was considered.
High confidence in phenotypic quality. ",0-1,0.0,0.75
198,"Bowling KM , et al. (2017): Genomic diagnosis for children with intellectual disability and/or developmental delay",28554332.0,00003-C,MECP2,: de novo,Variant is de novo non-canonical splice site,Low Confidence in Phenotype ,"ASD: The proband was recruited on the basis of primary diagnosis of mild/severe ID, as long as the condition cannot be explained by a known clinical condition such as inborn errors of metabolism or other syndromes. Probands also exhibited autistic features and other behavioral abnormalities, but these features had to be in conjunction with DD/ID phenotypes. Given that the focus of the clinical phenotype was not ASD, the methods used to assess the features of ASD were not described",,,,"Default score downgraded after modification for functional and phenotypic evidence 
De novo non-canonical splice variant identified through whole exome sequencing. The variant is absent in gnomAD. The variant was shown to create a cryptic acceptor splice site resulting in the addition of 5 aberrant nucleotides and the formation of a premature stop codon. Based on this evidence, the score was partially upgraded (+0.25). Experiments to determine how the variant affects at the cellular and organism level were not performed. No additional cases with autism/autistic features were reported, thus score upgrades were considered. 
On the other hand, the score was downgraded for low confidence in the phenotypic quality (-0.5)",0-1.5,1.0,0.75
199,"Zhang Q, et al. (2017): Familial cases and male cases with MECP2 mutations",28394482.0,"Family A, Proband II-1",MECP2,": Maternally Inherited (The mother did not have any symptoms. X-Chromosome inactivation analysis revealed a skewed pattern (86:14) in the mother, explaining the absence of phenotypic expression. The father was mentally normal and physically healthy)",Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, the clinical profile of the patients is consistent with the main features of ASD, including stereotypic hand movements and poor eye contact. The case did not meet the criteria for Rett syndrome",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Maternally inherited missense mutation identified by direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The variant was also inherited to the affected brother who was diagnosed with X-linked ID, but not ASD. The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. For these reasons, the variant was scored as predicted/proven null. However, the score was not further upgraded since it is a recurrent disease-causing mutation among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
The score was further downgraded for medium confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
200,"Zhang Q, et al. (2017): Familial cases and male cases with MECP2 mutations",28394482.0,"Family B, Proband II-2",MECP2,": Maternally Inherited (The mother had mild ID (IQ =75). She had almost no communication with her peer or strangers, only a little communication with her family members. She had problems understanding complicated issues and difficulty learning new skills. X-chromosome inactivation analysis showed an skewed pattern (80:20) in the mother.)",Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, the clinical profile of the patients is consistent with the main features of ASD, including poor eye contact and development of stereotypic hand movements. The patients fulfilled the criteria for atypical RTT or PSV",,,,"Default score downgraded for genotypic and phenotypic evidence.
Maternally inherited missense mutation identified through direct sequencing of MeCP2. Since MeCP2 was the only gene analzyed, the score was downgrade (-0.5). The non-synonymous substitution is absent in gnomAD, but it is reported as a pathogenic mutation by reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the missense mutation has been demonstrated by well-established in vitro and in vivo mouse models. Trangenic mice carrying this variant develop Rett-like phenotypes; and at the molecular level, the mutation affects the interaction of MeCP2 with transcriptional co-repressor complexes. For these reasons, the variant was scored as predicted/proven null. Although functional evidence is available, the score was not further upgraded since this mutation is recurrent in cases with Rett syndrome. This decision was made to avoid overstimating the score. 
Medium confidence in phenotypic quality (-0.25). Although conventional diagnosis of ASD was not determined in this case, her clinical profile is consistent with the main features of ASD. Furthermore, the mother who also carried the same mutation presents some autistic features. ",0-2,1.0,0.75
201,"Zhang Q, et al. (2017): Familial cases and male cases with MECP2 mutations",28394482.0,"Family C, Proband III-1",MECP2,: Maternally Inherited (The mother had learning difficulties at 5 years of age. She had some autistic behavior with no friends. X-chromosme inactivation analysis revealed a random pattern of inactivation 53:47. The maternal grandmother and maternal aunt had not mutation.),Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, the clinical profile of the patients is consistent with the main features of ASD, including stereotypic hand movements and poor eye contact",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Maternally inherited missense mutation identified by direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. For these reasons, the variant was scored as predicted/proven null. However, the score was not further upgraded since it is a recurrent disease-causing mutation among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
The score was further downgraded for medium confidence in phenotypic quality (-0.25). Although the case did not recevied a conventional diagnosis of ASD, her clinical profile is consistent with the main features of the condition. Furthermore, the mother who is also carrier of this non-synonymous change has autistic features. ",0-2,1.0,0.75
202,Yuen RK et al. (2017): Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder,28263302.0,AU078503 (Proband of multiplex family),MECP2,: de novo,Variant is de novo,High Confidence in Phenotype ,ASD: The probands included in the study were assessed using standardized tools including the ADOS and ADI-R. An ASD diagnosis of research quality was determined if the proband met the criteria for one or both of the diagnostic tools. A clinical ASD diagnosis was determined by an expert clinician if the proband met the criteria for ASD according to the DSM-IV or DSM-5 guidelines,,,,"Default score downgraded for genotypic evidence.
De novo frameshift deletion identified through whole exome sequencing and validated by Sanger sequencing. The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence in phenotypic quality. ",0-2.5,2.0,1.75
203,Yuen RK et al. (2017): Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder,28263302.0,1-0770-003 (Proband of simplex family),MECP2,: Unknwon Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype ,ASD: The probands included in the study were assessed using standardized tools including the ADOS and ADI-R. An ASD diagnosis of research quality was determined if the proband met the criteria for one or both of the diagnostic tools. A clinical ASD diagnosis was determined by an expert clinician if the proband met the criteria for ASD according to the DSM-IV or DSM-5 guidelines,,,,"Default score applied. 
Nonsense mutation of unknown inheritance identified through Whole genome sequencing and validated by sanger sequencing. The variant is absent in gnomAD but it is reported as a well-known pathogenic mutation in reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the varinant has been proven by well-established in vitro studies, showing that the variant impairs the non-methylated DNA binding affinity and the transcriptional repression activity. However, the score was not upgraded since this variant is a recurrent mutation in cases with Rett syndrome. This decision was made to avoid overestimating the score. 
High confidence in phenotypic quality. ",0-2,1.0,1.5
205,"Curie A, et al. (2017): Asperger syndrome and early-onset schizophrenia associated with a novel MECP2 deleterious missense variant",28230711.0,Patient 1 (Dizygotic twin),MECP2,": de novo (The mutation was not observed in blood-extracted DNA form the mother, suggesting germline mosaicism)",Variant is de novomissense,High Confidence in Phenotype ,ASD: Diagnostic assessment was performed with the Autism Diagnostic Observation Schedule - Generic (ADOS) and diagnosis was ascertained based on the DSM-IV criteria for Pervasive Developmental disorder and Schizophrenia by a psychiatrist. The case fulfilled the criteria for ASD on ADOS and Asperger syndrome on DSM-IV criteria,,,,"Default score downgraded for genotypic evidence. 
De novo missense variant identified through targeted sequencing of MeCP2. Since MeC2 was the only gene analyzed, the score was downgraded (-0.25). The non-synonymous variant is predicted to be germline mosaic in the mother since the same variant was detected in the dizygotic twin. Although in silico algorithms predict a damaging effect, functional experiments are not available. 
High confidence in phenotypic quality. ",0-1,0.0,0.25
209,"Olson HE, et al. (2015): Mutations in epilepsy and intellectual disability genes in patients with features of Rett syndrome",25914188.0,Patient 4,MECP2,": Presumed de novo (In the study, presumed de novo variants were interpreted when DNA samples from the parents were not available for sequencing)",Variant is predicted/Proven null ,Medium confidence in Phenotype ,"ASD: The cases included in the study have clinical features consistent with Rett syndrome but no definitive molecular diagnosis. Evaluation of the medical records, and clinical phenotyping were performed investigating clinical features such as epilepsy, EEG findings, MRI results, non-epileptic events, developmental history, physical examination and autistic features. The clinical description of the case in Supplementary table II, indicates that the case has autistic features, including midline stereotypies and poor eye contact. However, the methods used to ascertain the autistic phenotype were not described in the study",,,,"Default score downgraded for phenotypic evidence.
Although the authors defined the variant as presumed de novo, the inheritance pattern was not define since DNA samples from the parents was not available for testing. The variant was identified by Whole exome sequencing and validated by Sanger sequencing. The missense variant is a known mutation recurrently detected in cases with Rett syndrome and reported by several database as pathogenic (ClinVar and OMIM), while it is excluded from population control databases such as gnomAD. Furthermore, functional evidence supports the pathogenicity of the variant since it abolishes methylated DNA binding, which is critical for the normal function of protein. Furthermore, at the cellualr level, it was shown that the variant affects the maturation process of neurons. For these reason, the mutation was determined as predicted/proven null. No further upgraded were applied to the score, since this is a recurrent mutation in cases with Rett syndrome. This decision was made to prevent an overestimation of the final score. 
However, the score was downgraded for medium confidence in phenotypic quality (-0.25) . ",0-2,1.0,1.25
210,"Redin C, et al. (2014): Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing",25167861.0,APN-130,MECP2,: de novo,Variant is de novomissense,Low Confidence in Phenotype,"ASD: The proband is part of a cohort where the primary diagnostic criteria is unexplained ID. Inclusion criteria required the absence of recurrent Fragile X mutations or pathigenic CNV detected by aCGH. Cases were excluded if presented major congenital abnormalities or signs of mitochodrial disorders. Clinical data were recorded following a standardised clinical record highlighting prenatal history, developmental history, neurological and behavioural disorders. ID severity was assessed by medical geneticists upon clinical evaluation. On the other hand, description of the criteria used to ascertain the ASD diagnosis or tools to identify autistic features were not provided. However, the clinical description of the case includes autistic features",,,,"Default score downgraded for genotypic and phenotypic evidence.
De novo missense mutation identified by targeted sequencing of a panel of 217 genes associated with ID/ASD. Given the limited number of genes included in the panel, the score was downgraded (-0.1). The non-synonymous substitution is absent in gnomAD, but it is reported as a pathogenic mutation by reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the missense mutation has been demonstrated by well-established in vitro and in vivo mouse models. Trangenic mice carrying this variant develop Rett-like phenotypes; and at the molecular level, the mutation affects the interaction of MeCP2 with transcriptional co-repressor complexes. Although functional evidence is available, the score was not upgraded since this mutation is recurrent in cases with Rett syndrome. This decision was made to avoid overstimating the score. The other missense variants in the additional genes are not clinically relevant.
The score was further downgraded for low confidence in phenotypic quality (-0.25). ",0-1,0.0,0.15
211,"Redin C, et al. (2014): Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing",25167861.0,APN-142,MECP2,: de novo,Variant is de novo,Low Confidence in Phenotype,"ASD: The proband is part of a cohort where the primary diagnostic criteria is unexplained ID. Inclusion criteria required the absence of recurrent Fragile X mutations or pathigenic CNV detected by aCGH. Cases were excluded if presented major congenital abnormalities or signs of mitochodrial disorders. Clinical data were recorded following a standardised clinical record highlighting prenatal history, developmental history, neurological and behavioural disorders. ID severity was assessed by medical geneticists upon clinical evaluation. On the other hand, description of the criteria used to ascertain the ASD diagnosis or tools to identify autistic features were not provided. However, the clinical description of the case includes autistic features such as stereotypic behaviors. But no information regarding the social interaction and communication skills were reported",,,,"Default score downgraded for genotypic and phenotypic evidence. 
De novo nonsense mutation identified by targeted sequencing of a panel of 217 genes associated with ID/ASD. Given the limited number of genes included in the panel, the score was downgraded (-0.5). The variant is absent in gnomAD, but reputable databases interpreted the variant as pathogenic. Experimental data, from well-established in vitro and in vivo studies showed that the variant impairs the function of the protein, affecting the transcirption repressor activity and binding to interacting partners. However, the score was not upgraded since it is a recurrent mutation among affected individuals. This decision was made to prevent an overestimation of the score. 
The score was further downgraded for low confidence in phenotypic quality (-1). ",0-2.5,2.0,0.5
212,"Suter B, et al. (2014): Brief report: MECP2 mutations in people without Rett syndrome.",23921973.0,Patient SB,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: Structured psychological assessment for autism included an Autism Diagnostic Interview (ADIR), an Autism Diagnostic Observation Schedule (ADOS) and Bayley Infant Scales of Development and the Psychoeducational Profile-Revisited (PEP-R), performed by skilled child psychiatrists at Texas Childrens Hospital, the Raleigh Developmental Evaluation Center (DEC), and the Calgary Child Development Centre. Patients were also all evaluated and followed by at least one pediatric neurologist with expertise in RTT and related disorders",,,,"Default score downgraded for genotypic evidence.
Frameshift deletion of unknown inheritance identified by mutational analysis of MeCP2, the exact genotyping methods were not specified (-0.5). The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD at this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence in phenotypic quality. ",0-2,1.0,0.75
214,"Piton A, et al. (2011): Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia.",20479760.0,,MECP2,: de novo (Inheritance was confirmed and the variant was determined as putative de novo),Variant is de novomissense,High confidence in phenotype,"ASD: ASD diagnosis was determined based on the DSM-IV criteria, based on the evidence from ADI-R and ADOS-G. Diagnosis was determined by a psychiatrist. Exclusion criteria included patients with psychotic symptoms mainly caused by alcohol, drug abuse, or other clinical diagnosis including major cytogenetic abnormalities",,,,"Default score downgraded for genotypic evidence.
De novo missense variant identified through targeted sequencing of a panel of 113 X-linked synaptic genes. Given the limited number of genes included in the panel, the score was downgraded (-0.25). The variant is absent in gnomAD.  The non-synonymous variant changes a polar hydrophilic, Arginine amino-acid for a hydrophobic aromatic side change. The missense change is located within the NCoR/SMART interaction domain (NID), which is a hotspot region of pathogenic missense mutations. The current variant is in close proximity to the p.R306C, which is one of the most common mutations in Rett syndrome cases. This change (p.R306C) affects the binding affinity with the NCoR/SMRT complex, but the effect of the current non-synonymous change (p.R309W) is not known. Schnewolf-Greulich B, et al. (2016) PMID: 26936630 claimed that the p.R309W variant is incompletely penetrant, since it was detected in an unaffected mother, with random X-inactivation, but it leads to a phenotype that is not consistent with typical Rett syndrome. Furthermore, the variant is also clinically heterogenous with a wide spectrum of phenotypes observed in cases with this variant.
High confidence in phenotypic quality. ",0-1,0.0,0.25
215,"Psoni S, et al. (2010): Phenotypic and genotypic variability in four males with MECP2 gene sequence aberrations including a novel deletion.",20098342.0,Patient 1,MECP2,": Most likely de novo (The variant was not detected in the mother. Sequencing chromatograms showed two nucleotide peaks suggesting the presence of 2 cell lines in the proband. Therefore, the case is most likely mosaic. Sequencing analysis using hair roots reveled a normal sequence. But no other tissues were available for analysis. The level of mosaicims was not determined for this case. However, somatic mosaicism explains why this case has a milder phenotype compared to female carriers of this well-known mutation)",Mosaic ,Medium Confidence in Phenotype,"ASD: The case was recruited from a cohort of 11 male patients, who have been referred with suspected symptoms of Rett syndrome (RTT). The case exhibits autistic features and his symptoms are consistent with the hallmarks of ASD including ritualistic and stereotyped behaviors anf social withdrawal. Diagnosis of Asperger syndrome was considered during neurological evaluation",,,,"Default score downgraded for genotypic and phenotypic evidence.
Mosaic missense variant identified through mutational analysis of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.25). Since the level of mosaicims was not determined for this patient, and the MeCP2 mutation was not detected in the mother, the variant was assessed as a de novo missense mutation, with default score of 0.5. This missense mutation is absent in gnomAD but reported by reputable databases as a pathogenic mutation. Furthermore, the pathogenicity of the variant has been demonstrated by well-established in vitro experiments. The variant impairs the DNA binding affinity of the protein and affects the maturation process of neurons. Regardless of the functional evidence, the score was not upgraded since it is a recurrent variant among Rett syndrome patients. This decision was made to prevent an overestimation of the final score. 
The score was further downgraded due to medium confidence in phenotypic quality (-0.1). ",,0.0,0.15
216,"Adegbola AA, et al. (2009): A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype.",18989701.0,Single case,MECP2,": Paternally Inherited (His early childhood and mid-adolescence were characterized by severe episodic behavioral dyscontrol, hyperactivity, anxiety, and apathy. He had socialization and cognitive difficulties and received special schooling for the duration of his education. He had several DSM-III diagnosis including Attention Deficit Hyperactivity Disorder, Developmental Articulation Disorder with a residual chronic stutter in adulthood, Developmental Expressive Language Disorder, Developmental Coordination Disorder, and Developmental Reading Disorder)",Other variant type not predicted/proven null (not de novo),High Confidence in Phenotype,ASD: She was diagnosed with pervasive developmental disorder-not otherwise specified (PDD-NOS) based on symptoms consistent with ASD. Neuropsychiatric assessment confirmed the diagnosis of PDD-NOS,,,,"Default score applied.
Paternally inherited missense variant identified through targeted sequencing of MeCP2. The father also presents behavioral abnormalities. The non-synonymous variant is reported in gnomAD at extremely low allele frequency. On the other hand, reputable databases report the variant as a well-known pathogenic mutation. Functional experiments showed that the variant is hypomorphic decreasing the affinity to bind DNA by 40%. However, the variant is not null, for that reason the default score was set to 0.1. Although the variant is reported in gnomAD and the genotyping methods are not comprehensive, the default score was applied, since this variant is pathogenic supported by functional data and reported in several databases. 
High confidence in phenotypic quality. ",0-0.1,0.0,0.1
217,Bartholdi et al. (2006): Clinical profiles of four patients with Rett syndrome carrying a novel exon 1 mutation or genomic rearrangement in the MECP2 gene.,16630165.0,Patient 4,MECP2,: Unknown Inheritance (Only the maternal DNA was available for testing and she had a normal profile),Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, the patients exhibited autistic behavior characterized by lack of eye contact and development of stereotypical hand movements",,,,"Default score downgraded for genotypic and phenotypic evidence.
Intragenic deletion of exon 3 and 4 of MeCP2, detected by MLPA analysis targeting the gene. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The inheritance of the variant is unknown, although the deletion was not detected in the maternal sample. But paternal sample was not available. Deletions of multiple exons are not reported in gnomAD. 
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
218,"Saxena, A., et al (2006):  Lost in translation: translational interference from a recurrent mutation in exon 1 of MECP2",16155192.0,Patient 212. Single case reported in the study,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was determined for the case, but the methods used to ascertain the diagnosis were not reported. However, the case exhibited autistic traits including social disengagement and development of hand stereotypies, consistent with the main features of ASD",,,,"Default score downgraded for genotypic and phenotypic evidence.
Deletion of 11 nucleotides in the coding sequence of exon 1 of the MeCP2_e1 isoform. The deletion was detected by RT-PCR of RNA sample from the patient. Previous DNA sequencing of the coding exons 2-4 yielded normal results. The deletion was subsequently validated by DNA sequencing, targeting exon 1. Due to the targeted sequencing approach, the score was downgraded (-0.5). The deletion results in the creation of a premature stop codon based on the isoform e1 but the reading frame of e2 is intact. However, immunocytochemical analysis showed that protein expression of both protein isoforms is lost in 24-26% of the cells. Indicating that the deletion in exon 1 impairs protein translation of isoform e2. Analysis of the sequence where the deletion occurred showed that the mutated transcript formed more complex secondary structure which might interfere with protein translation. Therefore, based on these functional evidence, the variant was determine as predicted/proven null. No additional upgrades were inlcuded to the score based on functional evidence, since this variant has been recurrently reported in other cases with similar phentoype. This was done to avoid overestimating  the final score. This mutation is not reported in gnomAD, but is reported in OMIM and ClinVAR where it is interpreted as pathogenic in both databases. 
Finally, the score was further downgraded for medium confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
219,Abdul-Rahman et al. (2006): The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders.,16418599.0,Patient 1,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The cases included in this cohort were referred for molecular testing due to pervasive developmental disorder (PDD), autism, Asperger syndrome, or autistic features. The case was suspected with Rett syndrome and diagnosis was confirmed after molecular testing, Although, autistic-behavior is a well-described feature for this case, the patient did not necessarily meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Nonsense mutation of unknown inheritance identified by direct sequencing of MeCP2. Since it was the only gene analyzed, the score was downgraded (-0.5). The variant is absent in gnomAD but reputable resources report the variant as a well-known pathogenic mutation. The pathogenicity of the variant has been demonstrated by well-established in vivo and in vitro experiments. Transgenic mice models, harbouring this variant, develop severe features, resembling Rett-like phenotypes. At the molecular level, the variant impairs the transcriptional repressor activity of the protein. Regardless of the functional evidence, the score was not upgraded since, it is a recurrent mutation among Rett syndrome patients. This decision was made to prevent overestimating the score. 
The score was further downgraded due to low confidence in phenotypic quality. ",0-2,1.0,0.5
220,Abdul-Rahman et al. (2006): The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders.,16418599.0,Patient 2,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The cases included in this cohort were referred for molecular testing due to pervasive developmental disorder (PDD), autism, Asperger syndrome, or autistic features. The case was suspected with Rett syndrome and diagnosis was confirmed after molecular testing, Although, autistic-behavior is a well-described feature for this case, the patient did not necessarily meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Nonsense mutation of unknown inheritance identified by direct sequencing of MeCP2. Since this was the only gene investigated, the score was downgraded (-0.5). The variant is absent in gnomAD, but reputable databases interpreted the variant as pathogenic. Experimental data, from well-established in vitro and in vivo studies showed that the variant impairs the function of the protein, affecting the transcirption repressor activity and binding to interacting partners. However, the score was not upgraded since it is a recurrent mutation among affected individuals. This decision was made to prevent an overestimation of the score. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
221,Abdul-Rahman et al. (2006): The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders.,16418599.0,Patient 3,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The cases included in this cohort were referred for molecular testing due to pervasive developmental disorder (PDD), autism, Asperger syndrome, or autistic features. The case was suspected with Rett syndrome and diagnosis was confirmed after molecular testing, Although, autistic-behavior is a well-described feature for this case, the patient did not necessarily meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Frameshift deletion of unknown inheritance, identified through direct sequencing of MeCP2. Since it was the only gene analyzed, the score was downgraded (-0.5). The variant is absent un gnomAD. 
The score was further downgraded for low confidence in the phenotypic quality (-0.5).",0-2,1.0,0.5
222,"Masuyama T, et al. (2005): Classic Rett syndrome in a boy with R133C mutation of MECP2",16122633.0,Single male case from the family reported in the study,MECP2,": Maternally Inherited (Mild ID. While she displayed a small frame and mild scoliosis, no other abnormalities were identified)",Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case but the clinical profile is consistent with the main features of ASD. The patient developed stereotypical hand movements, restricted unusual interests and little interest towards people",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Although the family reported in this study has the same structure as family A reported by Zhang Q, et al. (2017) PMID: 28394482, and in both families this non-synonymous variant is maternally transmitted to both affected children, the clinical profiles of the cases  are subtantially different (Row: 103). The age and phentoype of the children are discordant and the phentoypes of the parents are different. Confirming that these families are unrelated. 
confidence in phenotypic quality. Maternally inherited missense mutation identified by direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. For these reasons, the variant was scored as predicted/proven null. However, the score was not further upgraded since it is a recurrent disease-causing mutation among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
The score was further downgraded for medium confidence in phenotypic quality (-0.25).",0-2,1.0,0.75
223,"Hagberg, B. et al. (2005):  Rett syndrome: long-term clinical follow-up experiences over four decades",16225825.0,Case S-2,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The patient was diagnosed with classical Rett syndrome stage IVB, meeting all the major criteria. Although conventional diagnosis of ASD was not determined, the clinical description of the patient included autistic features",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Nonsense mutation of unknown inheritance. The genotyping methods were not described (-0.5). The variant is absent in gnomAD but reputable resources report the variant as a well-known pathogenic mutation. The pathogenicity of the variant has been demonstrated by well-established in vivo and in vitro experiments. Transgenic mice models, harbouring this variant, develop severe features, resembling Rett-like phenotypes. At the molecular level, the variant impairs the transcriptional repressor activity of the protein. Regardless of the functional evidence, the score was not upgraded since, it is a recurrent mutation among Rett syndrome patients. This decision was made to prevent overestimating the score. 
The score was further downgraded due to low confidence in phenotypic quality. ",0-2,1.0,0.5
224,"Kleefstra T, et al. (2004): MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics.",14560307.0,Patient 1,MECP2,: de novo,Variant is de novo,Low Confidence in Phenotype,"ASD: The case's description includes autistic features/behavior. However, the assessments tools used to evalute the autistic features were not described in the study. No official diagnosis of ASD was determined for this case",,,,"Default score downgraded for genotypic and phenotypic evidence.
De novo nonsense mutation identified by targeted sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD, but it is reported in reputable databases, where it is interpreted as pathogenic. This variant has been observed in other cases with Rett syndrome including familial cases, where the variant co-segregates with the phenotype, suggesting that the variant is pathogenic. However, no functional studies have been carried out. 
The score was further downgraded due to low confidence in phenotypic quality (-1). ",0-2.5,2.0,0.5
225,"Kleefstra T, et al. (2004): MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics.",14560307.0,Patient 3,MECP2,": Mosaic mutation (The mutation is predicted to be mosaic; with a 25% of mutant to wild type allele fraction, estimated from lymphocytes. However, it is uncertain if this ratio is constant in brain tissue.)",Mosaic ,Low Confidence in Phenotype,"ASD: The case's description includes autistic features/behavior including stereotypic movements and lack of speech. However, the assessments tools used to evalute the autistic features were not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Somatic missense mutation identified by direct sequencing of the coding exons of MeCP2. Since MeCP2 was the only gene anlalyzed, the score was downgraded (-0.1). The variant was detected to be mosaic in the patient with an estimated variant allele fraction of 25% from lymphocyte samples. However, it is uncertain if this ratio is representative of brain tissues. Therefore, the variant might have arisen de novo during embryo development. For that reason the variant is interpreted as de novo missense with a default score of 0.5. The missense variant is absent in gnomAD, but reputable databases such a ClinVar and OMIM reports the variant as pathogenic. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, abolishing the ability of the protein to bind DNA. However, the score was not upgraded since it is a recurrent variant among affected cases with Rett syndrome. This was done to prevent overestimating the score. 
The score was further downgraded due to low confidence in phenotypic quality (-0.25). ",,0.0,0.15
228,"Carney RM, et al. (2003): Identification of MeCP2 mutations in a series of females with autistic disorder",12770674.0,Patient 1,MECP2,": Unknown Inheritance, but most likely de novo (The variant was not detected in the patient's mother nor in her 2 sisters; the paternal grandparents did not have the variant. However, DNA sample from the father was unavailable, and phenotypic information of the father was not provided)",Variant is predicted/Proven null ,High Confidence in Phenotype,"ASD: The cases included in this study had a pre-existing clinical diagnosis of Autistic disorder. Clinical records were reviewed to validate the medical and developmental history of the patient. Diagnosis of Autistic disorder was confirmed by ADI-R, following the diagnostic algorithm for Autistic disorder based on the DSM-IV and ICD-10 diagnostic criteria. The research participant was also assessed for her level of adaptive functioning using the Vineland Adaptive Behavior Scales (VABS). Individuals with medical disordes associated with ASD, including tuberous sclerosis complex, fragile X syndrome or structural brain abnormalities were excluded from the analysis. Furthermore, individuals with potential confounding factors such as significant prenatal and perinatal events were also excluded",,,,"Default score downgraded for genotypic evidence.
Frameshift deletion of unknown inheritance identified by mutational analysis of MeCP2, followed by direct sequencing. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence in phenotypic quality.",0-2,1.0,0.75
229,"Carney RM, et al. (2003): Identification of MeCP2 mutations in a series of females with autistic disorder",12770674.0,Patient 2,MECP2,: de novo,Variant is de novo,High Confidence in Phenotype,"ASD: The cases included in this study had a pre-existing clinical diagnosis of Autistic disorder. Clinical records were reviewed to validate the medical and developmental history of the patient. Diagnosis of Autistic disorder was confirmed by ADI-R, following the diagnostic algorithm for Autistic disorder based on the DSM-IV and ICD-10 diagnostic criteria. The research participant was also assessed for her level of adaptive functioning using the Vineland Adaptive Behavior Scales (VABS). Individuals with medical disordes associated with ASD, including tuberous sclerosis complex, fragile X syndrome or structural brain abnormalities were excluded from the analysis. Furthermore, individuals with potential confounding factors such as significant prenatal and perinatal events were also excluded",,,,"Default score downgraded for genotypic evidence. 
De novo nonsense mutation identified through mutational analysis of the coding regions of MeCP2  using denaturing high performance liquid chromatography followed by direct sequencing. Since MeCP2 was the only gene investigated, the score was downgraded (-0.5). The variant is absent in gnomAD but reputable databases interpreted the mutation as pathogenic (ClinVar and OMIM). Furthermore, the pathogenicity of the variant has been proved by well-established in vivo and in vitro experiments. The variant affects the transcriptional repression activity and reduced protein stability. However, the score was not upgraded since it is a recurrent variant among Rett syndrome patients. This decision was made to avoid overestimating the score. 
High confidence in phenotypic quality. ",0-2.5,2.0,1.5
230,"Moog U, et al. (2003):  Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2)",12615169.0,Single proband,MECP2,: de novo,Variant is de novomissense,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, some of his clinical features are consistent with ASD, including abnormal social approach, reservation towards strangers and fixation to sleep schedules",,,,"Default score downgraded for genotypic and phenotypic evidence. 
De novo missense variant identified through bi-directional sequencing of the coding regions of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.25). This amino-acid substitution is absent in gnomAD, but reputable databases report the variant was pathogenic. However, no functional evidence is available to support the pathogenicity of the variant. 
The score was further downgraded for medium confidence in the phenotypic quality (-0.1). ",0-1,0.0,0.15
231,"Smeets E, et al. (2003): Rett syndrome in adolescent and adult females: clinical and molecular genetic findings.",12966523.0,Patient 4,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The case exhibits autistiform traits including typical hand stereotypies. However, the methods used to assess the clinical phenotype of the case were not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Missense mutation of unknown inheritance identified by direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. For these reasons, the variant was scored as predicted/proven null. However, the score was not further upgraded since it is a recurrent disease-causing mutation among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
The score was further downgraded for low confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
232,Peter Huppke et al. (2003): The spectrum of phenotypes in females with Rett Syndrome,12850514.0,Case 3,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The case received a diagnosis of infantile autism. However, the methods used to determine the diagnosis were not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Frameshift deletion of unknown inheritance identified through mutational analysis of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD.
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
233,"Geerdink N, et al. (2002): MECP2 mutation in a boy with severe neonatal encephalopathy: clinical, neuropathological and molecular findings.",11930274.0,Affected sister in this pedigree,MECP2,": de novo (The frameshift variant was not identified in the mother, but maternal germline mosaicism is possbile, since the same mutation was identified in the brother. The brother had a severe phenotype characterized by neonatal encephalopathy and died at the age of 13 months)",Variant is de novo,Low Confidence in Phenotype,"ASD: The clinical description includes autistic features. However, the evaluation criteria and methods used to determine the autistic features were not described in the paper",,,,"Default score downgraded for genotypic and phenotypic evidence. 
De novo frameshift variant identifeid by direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD, but reputable sources report the variant as pathogenic. The variant segregated with the phenotype in the family. 
The score was further downgraded due to low confidence in phenotypic quality (-1). ",0-2.5,2.0,0.5
234,"Winnepenninckx B, et al. (2002): Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine screening?",12325019.0,Patient III-6; Family MRX79 (This is a three-generation family including 5 affected males),MECP2,: Maternally Inherited (This missense change was identified in all male patients with similar clinical profile. All female carriers in this three-generation family are unaffected),Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: This patient presents autistic behavior. However, the methods used to assess the clinical profile of the case was not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Maternally inherited missense variant identified through mutational analysis of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD but reputable resources report the variant as pathogenic. Furthermore, the variant is a recurrent mutation among male cases with non-syndromic X-linked ID. Functional evidence showed that the variant abolishes the interaction of MeCP2 with ATRX, an interacting partner. However, other functions such as DNA binding and transcriptional activity was not disrupted. Since evidence supports that the variant is pathogenic, the variant was interpreted as predicted/proven null.
However, the score was downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
235,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 307.FR,MECP2,: de novo,Variant is de novomissense,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score downgraded for genotypic evidence. 
De novo missense mutation identified through direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.25). The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. However, the score was not upgraded since it is a recurrent variant among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
High confidence in phenotypic quality. ",0-1,0.0,0.25
236,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 178.DM,MECP2,: de novo,Variant is de novomissense,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score downgraded for genotypic evidence.
De novo missense mutation identified by direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.25). The missense variant is a well-known pathogenic variant and one of the most recurrently identified variants in Rett syndrome cases. The variant is absent in gnomAD but it is interpreted as pathogenic by reputable databases. Functional evidence showed that the variant affects the binding to methylated DNA, which is critical for the function of the protein. Therefore, the missense variant in MeCP2 is the most likely disease-causing variant in the proband. However the score was not upgraded to avoid overestimating the score.
High confidence of phenotypic quality. ",0-1,0.0,0.25
237,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 64.MM,MECP2,: de novo,Variant is de novomissense,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score upgraded after modification for genotypic and functional evidence.
De novo missense mutation identified through direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.25). The variant is absent in gnomAD. This non-synonymous change affects the same resiude than the recurrent pathogenic variant p.T158M. Functional evidence from well-established in vivo and in vitro studies support the pathogenic effect of the varian. Transgenic mouse model carrying this variant recapitulates the major phenotypes of Rett syndrome. At the molecular level, the mutated protein lost its DNA binding affinity and its stability was reduced. Based on the compelling evidence, the score was upgraded (+0.5). Score was upgraded since no additional cases with this variant were reported with ASD/autistic features. 
High confidence in phenotypic quality. ",0-1,0.0,0.75
238,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 119.DA,MECP2,: de novo,Variant is de novomissense,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score downgraded for genotypic evidence.
De novomissense mutation identified through direct sequencing of MeCP2. Since MeCP2 was the only gene analzyed, the score was downgrade (-0.25). The non-synonymous substitution is absent in gnomAD, but it is reported as a pathogenic mutation by reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the missense mutation has been demonstrated by well-established in vitro and in vivo mouse models. Trangenic mice carrying this variant develop Rett-like phenotypes; and at the molecular level, the mutation affects the interaction of MeCP2 with transcriptional co-repressor complexes. Although functional evidence is available, the score was not upgraded since this mutation is recurrent in cases with Rett syndrome. This decision was made to avoid overstimating the score. 
High confidence in phenotypic quality. ",0-1,0.0,0.25
239,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 338.TG,MECP2,: de novo,Variant is de novo,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score downgraded for genotypic evidence.
De novoframeshift deletion identified mutational screening of MeCP2, followed by direct sequencing. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence in phenotypic quality.",0-2.5,2.0,1.25
240,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 169.BM,MECP2,: de novo,Variant is de novo,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score downgraded for genotypic evidence.
De novoframeshift deletion identified mutational screening of MeCP2, followed by direct sequencing. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence in phenotypic quality.",0-2.5,2.0,1.25
241,"Zappella M, et al. (2001):  Preserved speech variants of the Rett syndrome: Molecular and clinical analysis",11746022.0,Patient 139.CA,MECP2,": Maternally Inherited (The mother is asymptomatic. The variant was also detected in the sister who who diagnosed with a more severe phentoype consistent with classical Rett syndrome. X-chromosome inactivation analysis showed that the proband (patient 139.CA) had a random inactivation pattern (50:50), while the more affected sister had a borderline pattern of 66:34, with the mutant allele active in 66%. On the other hand, the mother had a highly skewed pattern of 99:1, explaining the absence of phenotypic consequences). Buschdorf and Stratling 2004 PMID: 14618241 investigated the role of the C-terminal region where the frameshift mutation is located and mapped a functional domain,which is required to bind specifically to Group II WW domains of splicing factors formin-binding protein FBP-11 and HYPC WW, both in vivo and in vitro. A truncated protein at position 400 was defective in binding to FBP1 and HYPC WW domains in vitro and in vivo.",Variant is predicted/Proven null ,High Confidence in Phenotype,ASD: The cases included in this study were evaluated in the Department of Child Neuropsychiatry. Diagnosis of autism was determined according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria and with the Childhood Autism Rating Scale (CARS),,,,"Default score downgraded for genotypic evidence.
Maternally inherited frameshift deletion identified mutational screening of MeCP2, followed by direct sequencing. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The mother is unaffected carrier, and the lack of phenotypic consequences is due favorable skewed X-inactivation. The frameshift deletion is located in a mutational hotspot where similar deletions have been detected in cases with milder phenotypes, associated with Rett syndrome and ASD. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence in phenotypic quality.",0-2,1.0,0.75
242,"Bienvenu T, et al. (2001): Five novel frameshift mutations in exon 3 and 4 of the MECP2 gene identified in Rett patients: Consequences for the molecular diagnosis strategy",11524737.0,Patient 1 (Table 1),MECP2,": Unknown Inheritance most likely de novo (the mutation was not detected in the mother. However, paternal sample was not available for testing. However, due to the severe phenotype, commonly observed in males, due to loss-of-function MeCP2 mutations, it is most likely that the variant is de novo.)",Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The case was diagnosed with classical Rett syndrome and autism. However, the criteria used to ascertain the diagnosis of ASD was not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Frameshift deletion of unknown inheritance identified by direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). Although the variant is most likely de novo since it was not detected in the mother, paternal sample was not available for testing. Since loss of function variants in MeCP2 cause severe phenotypes in males, it is unlikely that the variant was paternally inherited. But experimental confirmation is needed. The frameshift deletion is absent in gnomAD. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
243,"Bienvenu T, et al. (2001): Five novel frameshift mutations in exon 3 and 4 of the MECP2 gene identified in Rett patients: Consequences for the molecular diagnosis strategy",11524737.0,Patient 2 (Table 1),MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The case was diagnosed with classical Rett syndrome and autism. However, the criteria used to ascertain the diagnosis of ASD was not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Frameshift deletion of unknown inheritance identified by direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The frameshift deletion is absent in gnomAD. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
244,"Bienvenu T, et al. (2001): Five novel frameshift mutations in exon 3 and 4 of the MECP2 gene identified in Rett patients: Consequences for the molecular diagnosis strategy",11524737.0,Patient 5 (Table 1),MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,"ASD: The case was diagnosed with classical Rett syndrome and autism. However, the criteria used to ascertain the diagnosis of ASD was not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Frameshift deletion of unknown inheritance identified by direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is located in a mutational hotspot where similar frameshift deletion have been reported in cases with Rett syndrome. The frameshift deletion is absent in gnomAD. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5). ",0-2,1.0,0.5
246,"Lebo R, et al. (2001): Rett syndrome from quintuple and triple deletions within the MECP2 deletion hotspot region",11453972.0,Propositus 1,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Although the case's clinical profile is consistent with the main features of autistic behavior, conventional diagnosis of ASD was not established based on standardized criteria",,,,"Default score downgraded for genotypic and phenotypic evidence.
Complex frameshift deletion of unknown inheritance identified through direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD. 
The score was further downgraded due to medium confidence in phenotypic quality (-0.25). The case description includes autistic behavior and her symptoms are consitent with the main symptoms of ASD, including abnormal behavior in different social context, poor eye contact and presence of repetitive hand-wringing movements. ",0-2,1.0,0.75
247,"Lebo R, et al. (2001): Rett syndrome from quintuple and triple deletions within the MECP2 deletion hotspot region",11453972.0,Propositus 2,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Low Confidence in Phenotype,ASD: Cconventional diagnosis of ASD was not established based on standardized criteria. The patient's description includes the presence of typical autistic behavior including stereotypic behavior. But no description of her socio-emotional performace was provided,,,,"Default score downgraded for genotypic and phenotypic evidence.
Complex frameshift deletion of unknown inheritance identified through direct sequencing of MeCP2. Given the targeted sequencing approach, the score was downgraded (-0.5). The variant is absent in gnomAD. 
The score was further downgraded due to low confidence in phenotypic quality (-0.5).",0-2,1.0,0.5
248,"Yamashita Y, et al. (2001): Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech",11738864.0,Patient 1,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, her clinical profile is consistent with the main features of ASD inlcuding poor social interaction, emotional withdrawal and the presence of hand-washing stereotypies",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Missense mutation of unknown inheritance identified by direct sequencing of MeCP2. Since MeCP2 was the only gene analyzed, the score was downgraded (-0.5). The non-synonymous mutation is absent in gnomAD but, it is interpreted as pathogenic by reputable databases such as ClinVar and OMIM. Furthermore, well-established in vitro experiments showed that the variant affects the function of the protein, reducing the ability to bind DNA and interact with protein partners. For these reasons, the variant was scored as predicted/proven null. However, the score was not further upgraded since it is a recurrent disease-causing mutation among affected cases with Rett syndrome. This decision was made to prevent overestimating the score. 
The score was further downgraded for medium confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
249,"Yamashita Y, et al. (2001): Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech",11738864.0,Patient 2,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, her clinical profile is consistent with the main features of ASD including poor eye contact with people and the presence of hand-washing stereotypies",,,,"Default score downgraded for genotypic and phenotypic evidence.
Missense mutation of unknown inheritance identified through direct sequencing of MeCP2. Since MeCP2 was the only gene analzyed, the score was downgrade (-0.5). The non-synonymous substitution is absent in gnomAD, but it is reported as a pathogenic mutation by reputable databases such as OMIM and ClinVar. Furthermore, the pathogenicity of the missense mutation has been demonstrated by well-established in vitro and in vivo mouse models. Trangenic mice carrying this variant develop Rett-like phenotypes; and at the molecular level, the mutation affects the interaction of MeCP2 with transcriptional co-repressor complexes. For these reasons, the variant was scored as predicted/proven null. Although functional evidence is available, the score was not further upgraded since this mutation is recurrent in cases with Rett syndrome. This decision was made to avoid overstimating the score. 
The score was further downgraded due to medium confidence in the phenotypic quality (-0.25). ",0-2,1.0,0.75
250,"Yamashita Y, et al. (2001): Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech",11738864.0,Patient 4,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of ASD was not determined for this case. However, her clinical profile is consistent with the main features of ASD including inappropriate behavior with people and the presence of hand-wringing stereotypies",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Nonsense mutation of unknown inheritance identified through mutational analysis of the coding regions of MeCP2 using denaturing gradient gel electrophoresis followed by direct sequencing. Since MeCP2 was the only gene investigated, the score was downgraded (-0.5). The variant is absent in gnomAD but reputable databases interpreted the mutation as pathogenic (ClinVar and OMIM). Furthermore, the pathogenicity of the variant has been proved by well-established in vivo and in vitro experiments. The variant affects the transcriptional repression activity and reduced protein stability. However, the score was not upgraded since it is a recurrent variant among Rett syndrome patients. This decision was made to avoid overestimating the score. 
The score was further downgraded for medium confidence in phenotypic quality (-0.25). ",0-2,1.0,0.75
251,"Yamashita Y, et al. (2001): Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech",11738864.0,Patient 5,MECP2,: Unknown Inheritance,Variant is predicted/Proven null ,Medium Confidence in Phenotype,"ASD: Conventional diagnosis of Autistic disorder was determined at the age of 40 months. Furthermore, her clinical profile is consistent with the features of ASD. However, the criteria used to determined the diagnosis of ASD was not described in the study",,,,"Default score downgraded for genotypic and phenotypic evidence.
Frameshift deletion of unknown inheritance identified through mutational analysis of MeCP2. Given the targeted approach, the score was downgraded (-0.5). The variant is absent in gnomAD and predicted to result in a premature stop codon. 
The score was further downgraded due to medium confidence in phenotypic quality (-0.25).",0-2,1.0,0.75
253,"De Bona C, et al. (2000): Preserved speech variant is allelic of classic Rett syndrome",10854091.0,Case 32,MECP2,: likely de novo (possibility of germline mosaicism was not excluded),Variant is de novo,Medium Confidence in Phenotype,"ASD: The case was diagnosed with preserved speech variant, a syndrome with similar phenotypic characteristics to Rett syndrome. Conventional diagnosis of ASD was not established for this case, but her clinical phenotype includes features characteristic of ASD, including stereotypical hand movement, echolalia and lost the ability to relate to other",,,,"Default score downgraded for genotypic and phenotypic evidence. 
Likely de novo frameshift deletion variant identified by direct sequencing of the coding regions of the MECP2 gene. Mutational analysis of the variant suggest the variant is de novo but parental germline mosaicism cannot be ruled out. Given that the genotyping approach was restricted to MEPC2 gene and no genome-wide analysis was performed, the score was downgraded (-0.5). The variant is located near direct repeats ('ACCCC and CCCCACC  CCTGAGCCC), which explains why this is a mutational hotspot with several patients carrying similar deletions in this region. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
The score was further downgraded for medium confidence in phenotypic quality (-0.5).",0-2.5,2.0,0.75
254,"De Bona C, et al. (2000): Preserved speech variant is allelic of classic Rett syndrome",10854091.0,"Case 109 (Detailed clinical information was provided by Zappella e t al.(1998) PMID: 9932238; case ID: Case I-12, in this study, the patient was reported for the first time)",MECP2,: likely de novo (possibility of germline mosaicism was not excluded),Variant is de novo,High Confidence in Phenotype,ASD: According to Zappella et al. (1998) PMID: 9932238. The case fulfilled the criteria for Autistic disorder based on the DSM-IV guidelines,,,,"Default score downgraded for genotypic evidence.
Likely de novo frameshift deletion variant identified by direct sequencing of the coding regions of the MECP2 gene. Mutational analysis of the variant suggest the variant is de novo but parental germline mosaicism cannot be ruled out. Given that the genotyping approach was restricted to MEPC2 gene and no genome-wide analysis was performed, the score was downgraded (-0.5). The variant is located near direct repeats ('ACCCC and CCCCACC  CCTGAGCCC), which explains why this is a mutational hotspot with several patients carrying similar deletions in this region. Since this variant creates a premature stop codon in a gene where loss-of-function mutations are a known disease mechanism, this variant is most likely null. In fact, it was shown that the C-terminal region is necessary for interactions of the MeCP2 protein with WW containing proteins. A protein truncated at position 400, was defective in protein binding. But the biological implications of this disruption is not completely known. On the other hand, the score was downgraded since several, similar frameshift variants have been reported in gnomAD in this region. Moreover, these truncating variants happen in the last exon of the gene and might escape the non-sense mediated mRNA decay. For that reason, these mutations are observed in cases with milder phenotypes (-0.25) 
High confidence of phenotypic quality.",0-2.5,2.0,1.25
256,"Kim SJ, Cook EHJ (2000):  Novel de novo nonsense mutation of MECP2 in a patient with Rett syndrome",10737989.0,Single case,MECP2,: de novo,Variant is de novo,Low Confidence in Phenotype,"ASD: The primary pediatric neurologist had not diagnosed RTT after following her for over 3 years, but a consulting pediatric neurologist determined the diagnosis of RTT. The patients was ascertained from an autistic clinic and presents some characteristic features of autistic disorder. The case was also ascertained with autistic disorder but the methods used to assess the phenotype of the case were not described",,,,"Default score downgraded for genotypic and phenotypic evidence.
De novo nonsense mutation identified through targeted sequencing of MeCP2. Given the targeted approach, the score was downgraded (-0.5). This is the most severely truncated variant identified in a case and is absent in gnomAD. 
However, the score was further downgraded due to low confidence in phenotypic quality (-1). ",0-2.5,2.0,0.5
260,"Nagarajan RP, et al. (2006): Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation.",17486179.0,,MECP2,,Expression,High Quality in Experimental Evidence,,,,,"Default score applied. 
The study investigated the level of MeCP2 expression in two brain regions (frontal cortex and fusiform gyrus, which are functionally relevant for autism etiology) from brain samples of autistic patients and other related neurodevelopmental disorders. Both at the transcript and protein level, the expression of MeCP2 was significantly and consistently reduced in brain samples from autistic patients, compared to age-matched controls. The decreased expression of the gene was correlated with increased methylation of the promoter region of the gene. Therefore, these results showed that abnormal epigentic control of MeCP2 expression might underlie the etiology of ASD, even in the absence of MeCP2 coding and regulatory mutations.",0-2,0.0,0.5
